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11     Presentation of the thesis 
1.1 Introduction
The sunshine’s fading effect on the yellow skin colour of jaundiced newborns was 
discovered accidentally by an observant nurse in 1956. The first, controlled treatments 
of the condition of hyperbilirubinaemia (jaundice) were indeed performed with 
sunlight as the light source (Cremer et al. 1958), but were very soon followed by the 
use of blue-light fluorescent lamps. These lamps emitted light in the spectral range of 
420-480 nm (visible light) (Fig. 1.1), and the treatment was given interrupted by 
breaks (intermittently). 
Fig. 1.1 The electromagnetic spectrum (Alonso and Finn 1967) 
Two decades prior to the first phototherapy events, scientists had discovered the 
photoreactivity of bilirubin in in vitro systems. Saeki (1932) exposed red blood cells 
to bilirubin and light, and observed a resulting photohaemolysis. A few years later, 
Fischer and Herle (1938) found that bilirubin solutions gradually lost their 
characteristic colour when left in daylight. Cremer et al. (1958) used the latter 
observation as a model to explain the more rapid recovery of jaundiced newborns 
after exposure to visible light. The loss of bilirubin observed was thought to be a 
result of photooxidation or dehydrogenation of the bilirubin pigment to biliverdin (a 
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2breakdown product of bilirubin) or other pigments. Even as late as in the seventies, 
when phototherapy had become an established and preferred mode of treatment, 
photooxidation was thought to be the mechanism responsible for the bilirubin loss 
(McDonagh 1971). However, McDonagh and coworkers were among the first 
researchers to show that bilirubin can undergo several other photoreactions than 
photooxidation, notably photoisomerisation (McDonagh et al. 1979). Today, 
photoisomerisation is considered the main photochemical mechanism behind the 
effect of phototherapy (see 1.2.2). 
Two factors characterising the use of phototherapy of jaundiced newborns today are 
the lack of standardisation and the unconscious employment. Generally, phototherapy 
is administered in much the same way as in the early days of treatment. Variations in 
therapeutic light colour and fractionation regimens have been tried and advocated, but 
the number of high quality clinical studies is sparse. New types of equipment of 
varying suitability have been taken into use without thorough clinical follow-up 
studies. The bulk of phototherapy research has been done on adverse effects, but 
unfortunately only a small part is relevant for in vivo conditions. Not enough attention 
has been paid to the light physics. Lack of calibration of equipment and radiometers, 
variability of lamp systems used resulting in considerable differences in irradiance 
and lack of standardisation of light physics nomenclature are all factors making the 
comparison of treatment results more difficult. These concerns were expressed by 
medical physicists in several abstracts presented at the October 2002 meeting of the 
Institute of Physics and Engineering in Medicine (IPEM 2003).
There is a need for improvement and optimisation of phototherapy. In order to reach 
these goals, more clinical studies with emphasis both on therapeutic and adverse 
effects, and systematic in vitro studies should be carried out. The studies should 
always be undertaken prior to changes in the treatment, along with follow-up studies, 
to assure that newborns are given the best possible treatment with the least adverse 
effects and to ensure the ethical considerations related to research on children (Roll 
and Christensen 1997 (paper 2)). 
With the above-mentioned goals in mind, a multi-centre clinical study of a newborn, 
jaundiced cohort was planned and partly carried out in three Norwegian hospitals.
Prior to the onset of the study, there was a need for a theoretical investigation of the 
basis for and perspectives of the trial as well as assessment of the ethical 
considerations implied. The objectives of the clinical study were as follows: first, to 
compare differences between therapeutic light colours to determine whether turquoise 
fluorescent light tubes will give a faster bilirubin clearance in serum than will blue 
fluorescent light tubes. Second, to attempt to identify the optimal irradiance for 
overhead phototherapy units equipped with blue fluorescent light tubes (Fig.1.2). 
Finally, to determine whether an equally good therapeutic effect can be obtained by a 
smaller total light dose separated by dark periods compared with a continuous 
treatment. For all the parameters under investigation, the influence of irradiation on 
light sensitive vitamins in serum was to be assessed. 
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3Fig. 1.2 Overhead phototherapy lamp with light tubes. 
Another cohort of hyperbilirubinaemic newborns was subjected to a non-invasive 
bilirubin measurement technique of reflectance spectroscopy to study differences in 
skin optical parameters such as melanin and erythema indices of patients undergoing 
phototherapy. Furthermore, we wished to correlate the bilirubin index found by the 
non-invasive technique to the total serum bilirubin.  
To further evaluate possible adverse effects of phototherapy in vitro, we wanted to 
investigate differences in cytotoxic effects related to variations in the parameters 
examined in the clinical study described in papers 1, 2 and 4. In addition, the 
phototherapy effects were to be compared to dark toxicity of bilirubin. These in vitro
investigations included examination of possible cytotoxic mechanisms; apoptosis and 
necrosis. Furthermore, studies were performed to reveal possible haematological 
consequences of phototherapy in jaundiced newborns. The phenomena chosen as end-
points were increased osmotic fragility and delayed photohaemolysis of both normal 
erythrocytes and spherocytes obtained from a donor with hereditary spherocytosis. 
On this background, the parts and papers presenting the in vivo and in vitro studies are 
as follows (Throughout this thesis the word “paper” has been used equivalent to the 
word “chapter” when the eight chapters contained in the thesis are presented): Part I 
consists of two papers related to the planning of clinical studies. The first paper 
describes the need for optimisation of phototherapy with emphasis on the physical 
parameters such as wavelength and light intensity, and a thorough evaluation of the 
therapeutic efficiency and possible side effects of the treatment. A planned 
epidemiological study that will concentrate on long-term side effects, particularly in 
relation to cancer development is also described. The second paper deals with the 
ethical considerations related to research on children using the Declaration of Helsinki 
and various paediatric directions as references. The ethical aspects needed to be 
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4discussed in connection with the above-mentioned clinical phototherapy study are 
evaluated.
Results from our clinical studies are given in Part II. Paper 3 contains analyses of 
reflection spectra of the skin of jaundiced newborns exposed to phototherapy 
compared to a group not given the treatment. Factors influencing the skin optics of 
newborns are discussed, as well as the bilirubin kinetics. Paper 4 gives a detailed 
description of the planned clinical phototherapy study referred to in the papers in Part 
I as well as a presentation of results of riboflavin (vitamin B2) and retinol (vitamin A) 
serum analyses of the newborn patients’ blood. 
In vitro systems have the advantage of demonstrating effects on a large scale in a 
short time without the concurrent influence of the whole-body biochemical and 
physiologic action, especially where such studies will be a major strain on human 
subjects. Three papers examining effects of bilirubin and visible irradiation on cells 
are found in Part III. The first evidence for apoptotic cell death of the mouse 
lymphoma cell line L5178Y-R (LY-R) exposed to bilirubin and blue phototherapy 
light is presented in paper 5. The finding of apoptosis in cells subjected to bilirubin in 
the dark has later been confirmed by other groups (Tibbs et al. 2000, Silva et al. 
2001). A comparison of fractionated and continuous irradiation on cell death was 
performed in paper 6, whereas differences in cytotoxicity after blue and turquoise 
irradiation was the topic of paper 7. In papers 5 and 7, high pressure liquid 
chromatography analysis was used as an additional method to study the production of 
photoisomers of bilirubin and the reduction of unconjugated bilirubin to indicate 
efficiency of the irradiation and the possible formation of photooxidation products. 
In the last section of Part III, paper 8 provides a continuation of the first published 
findings by Saeki in 1932 of photohaemolysis of red blood cells after exposure to 
bilirubin and blue light. In the study, a possible difference in the sensitivity of normal 
erythrocytes and spherocytes from a patient with hereditary spherocytosis is 
addressed. The risk of phototherapy-induced haemolysis is discussed. 
The first chapter of this thesis will provide a general background for the most 
important matters related to phototherapy. Many subjects are thoroughly described in 
the two papers in Part I, and are also discussed in the remainder of the papers where 
appropriate. This chapter will, therefore, concentrate on items not covered in the 
papers and more recent research that has been published after the papers presented in 
Part I. A short presentation of each paper will be given followed by a general 
discussion of the results and suggestions for future work. 
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51.2 Phototherapy of neonatal hyperbilirubinaemia (jaundice) 
1.2.1 Physiology of hyperbilirubinaemia 
(Main references: Cashore 1998 and Jährig et al. 1993b). 
Elevated bilirubin concentration in the serum of newborn infants causing yellow skin 
colour is due to a normal physiological condition. Concentrations five to seven times 
higher than those of normal adults occur in more than 50 % of Caucasian newborns 
(lower in African-Americans and higher in Asians (Maisels 1995)). The term 
hyperbilirubinaemia refers to concentration levels of bilirubin above defined limits 
and may be caused by normal physiological influences as well as pathological (e.g., 
liver diseases, haemolysis). 
There are four main causes for the elevated serum bilirubin concentration in the 
neonate. First, bilirubin, being a catabolite of haem, must be excreted by the newborn 
itself without the previous fetal help of its mother, giving rise to some novice 
complications. The erythrocytes (containing haemoproteins) in excess have to be 
broken down in the newborn baby when the oxygen supply starts to be provided by 
the infant’s own respiration. The breakdown process may occur at a higher rate than 
does the formation of new erythrocytes. Second, the transport mechanisms for 
bilirubin in the vascular (albumin) and hepatic (ligandin) systems may not have been 
fully developed. Third, there may be immaturity of the liver enzymes, especially of 
the bilirubin uridine-diphosphate glucoronyl transferase (UDGT) responsible for 
making the lipophilic bilirubin molecule water-soluble and bile-excretable 
(conjugation). Finally, deconjugated and unconjugated bilirubin may be reabsorbed 
from the intestine and recirculated in the blood stream contributing to an elevation of 
the bilirubin concentration (a phenomenon called rebound). Genetic deficiency of the 
UDGT leads to Gilbert’s and Crigler-Najjar syndromes, of which the latter causes 
chronic hyperbilirubinaemia (Arias et al. 1969). 
The reason behind the need for treatment, which is performed by phototherapy in the 
overwhelming majority of cases, is the neurotoxic effect of unconjugated, unbound 
bilirubin. In this form, bilirubin causes the often mild and reversible bilirubin 
encephalopathy, the more severe irreversible neurological damage or the deadly 
outcome, kernicterus. Normally, the blood-brain barrier is impermeable to albumin 
and albumin-bound bilirubin. Certain clinical conditions may, however, render the 
barrier more permeable, thereby increasing the possibility of transport of bilirubin into 
the brain (see Bratlid 1990 for a review). Bilirubin toxicity is not restricted only to the 
central nervous system, but may affect many different cell processes, as has been 
demonstrated in various cell lines in vitro (Karp 1979). In combination with visible 
light, bilirubin can act as a sensitiser with possible phototoxic effects on various cell 
components (Rosenstein et al. 1983, Christensen 1984).
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61.2.2 Bilirubin photochemistry 
(Main references: Ennever 1998 and Bonnett 2000). 
The formal nomenclature of the native, unconjugated bilirubin is 4Z,15Z-bilirubin 
IXĮ, being a derivative of protoporhyrin IX opened at the Į-carbon bridge and having  
Z-configurations, as opposed to E-configurations, at the carbon 4 and 15 positions 
(Fig.1.3). Due to the folded structure of the tetrapyrrole molecule with its internal 
hydrogen bonds, the polar groups cannot interact with the aqueous environment, 
rendering the molecule highly lipophilic. This feature complicates biliary and urinary 
excretion of bilirubin, but facilitates transport through tissue membranes. 
The bilirubin molecule can absorb light of certain wavelengths. Bound to albumin, the 
absorption maximum of bilirubin in vitro is 460 nm. When albumin is co-bound to 
fatty acids in vivo, this absorption maximum is shifted to about 480 nm (Malhotra et 
al. 1987). Upon absorption of a photon, the bilirubin is excited to a higher energy 
state. The molecule loses its energy to photochemical reactions, which are the desired 
outcome of phototherapy. Heat production is a more likely event whereas 
fluorescence (photon emission) is less likely to occur than a photochemical reaction. 
When photons cause rearrangements (involving a brief cleavage and reforming of a 
double bond) of the 4Z,15Z-bilirubin molecule (for short: ZZ-bilirubin) around the 4 
or 15 carbon positions, configurational photoisomers are formed: 4Z,15E; 4E,15Z and 
4E,15E (for short: ZE-, EZ- and EE-bilirubin, respectively). The formation of the 
isomers is photochemically reversible. The isomerisations cause less internal 
hydrogen bonding of the molecules, which make them more water-soluble. However, 
in vivo the configurational photoisomers are not the main isomers responsible for the 
bilirubin clearance as only very small quantities of the ZZ- and the ZE-isomers 
(isomerising back to ZZ-) are found in the bile and none in the urine of light treated 
patients (McDonagh and Lightner 1985) (Fig. 1.3). 
The principal excretory pathway of bilirubin is through the structural photoisomer, 
lumirubin. This isomer is formed by binding of two of the pyrrole rings of the 
molecule, giving rise to a new structure (Fig. 1.4). Lumirubin can be formed in a one-
photon process from ZZ-bilirubin or, more likely, in a two-photon step through the 
EZ-isomer. Lumirubin is more water-soluble than the configurational isomers, and its 
photoreaction back to ZZ-bilirubin is possible, but slow. Furthermore, lumirubin is 
rapidly excreted into the bile (Ennever et al. 1987) and urine (Knox et al. 1985, Onishi 
et al. 1980), and its serum concentration increases with increasing irradiance. 
Altogether, these characteristics make lumirubin the best candidate for bilirubin 
elimination.  
A third group of photochemical products of bilirubin is the photooxidation products 
consisting of one or two pyrrole rings. Being polar molecules, they are readily 
excreted by the kidneys into the urine, but quantitatively they are not as important as 
lumirubin. In reactions with oxygen, the excited bilirubin molecule may transfer its 
energy to give singlet oxygen (McDonagh 1971), although this reaction has low 
quantum efficiency (Sloper and Truscott 1982). In a study using an infrared 
spectroscopic method, the singlet oxygen production could not be detected (Roll et al. 
2001). On the other hand, bilirubin can both interact with singlet oxygen to quench 
the excited molecule physically, and it can also react with singlet oxygen chemically. 
It has been shown that irradiated bilirubin can form other reactive oxygen species 
URN:NBN:no-7250
7such as hydrogen peroxide and other peroxides (Rosenstein et al. 1983, Christensen 
1986).
Fig. 1.3 Photoisomerisation of 4Z,15Z-bilirubin to configurational photoisomer 4Z,15E. Hydrogen 
bonds are denoted with ”IIIIII”. Copied with permission of Prof. Raymonnd Bonnett (Bonett 2000).
The wavelength of the phototherapeutic light is of importance for the efficiency of the 
lowering of bilirubin concentration in serum. The in vivo shift in absorption spectrum 
of bilirubin has been mentioned already. The longer wavelength blue-green or green 
light reaches deeper into the skin than does light with shorter wavelengths, thus 
reaching more of the skin- and vascular bilirubin. Albumin-bound bilirubin also 
shows an increase in quantum efficiency of formation of lumirubin with increasing 
wavelengths in the range of 450-510 nm (Onishi et al. 1986, Vecchi et al. 1986, 
Greenberg et al. 1987, Itoh et al. 1987, McDonagh et al. 1989). 
URN:NBN:no-7250
8Fig. 1.4 A structural photoisomer of 4Z,15Z-bilirubin, lumirubin. Copied with permission of Prof. 
Raymonnd Bonnett (Bonett 2000).
1.2.3 Phototherapy today 
A presentation on phototherapy practice with regard to equipment, medication and 
physical parameters, such as wavelength, irradiance and fractionation, is given in 
paper 1 of this thesis. In this paragraph only additional and new information will be 
considered.
There is no reason to believe that the present number of newborns undergoing 
phototherapy for the treatment of jaundice has decreased from the estimated 5-10 % 
previously reported in Norway. This number is dependent on such factors as changes 
in inclusion criteria, changes in hospitalisation routines, the number of premature 
births and changes in the maternal health. For instance, health reports on the increase 
in the number of neonates born during the nineties, weighing more than 4 kg (Medical 
Birth Registry of Norway 2003) and the corresponding neonatal complications, such 
as unstable glucose levels and forceps delivery (Henriksen, National Hospital, 
personal communication), indicates a potentially higher prevalence of phototherapy. 
An increase in the number of newborns with high birth weights may also reflect a 
higher incidence of maternal diabetes, a condition known to increase the risk for 
hyperbilirubinaemia (Maisels 1988). Furthermore, the early discharge practices in the 
USA, combined with an increase in the prevalence of breast-feeding, however 
inadequately established, have increased the number of hospital readmissions and 
severe cases of hyperbilirubinaemia (Harris et al. 2001, Galbraith et al. 2003). 
The conclusions reached in an international survey conducted by Hansen (1996) on 
approaches to neonatal jaundice coincided with those of Christensen in three previous 
national studies with respect to the large diversity of phototherapy equipments and 
regimens in use and the lack of precise procedures (Christensen and Reitan 1987, 
Christensen et al. 1992). However, the latest national inspection by the Norwegian 
Radiation Protection Authority (NRPA)(autumn, 2002) of neonatal intensive care and 
well-baby units, displayed a higher degree of homogeneity of equipments, lamps and 
procedures compared to previous investigations. Unfortunately, in some hospitals 
there are still irradiation devices in use that have been advised against (Christensen, 
unpublished results). 
The most frequent phototherapy equipment used in Norwegian hospitals is blue 
fluorescent tubes in combination with white light. Relatively few units use light 
mattresses or fiberoptic blankets, and these devices are seldom seen in the neonatal 
intensive care units. In 1998 one of the major national paediatric units bought a large 
number of the so-called “Bili-compact” lamps consisting of 10 × 9W1114 (compact) 
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9tubes with a peak emission of 460 nm (blue). The irradiance of the light tubes was 
measured and found satisfactory, however, the irradiance area was small (a 50 % 
decrease in maximum irradiance measured 30 cm from the midpoint of the lamp), 
substantiating less than optimum irradiation to the patient (Bruzell Roll and Riise, 
unpublished results). This problem is partly solved by increasing the light irradiance 
by covering the top and sides of the units with white, reflecting and scattering textiles 
as advised by the NRPA (Eggert et al. 1988, Amundsen 1991). 
A new blue-green phototherapy lamp was tested in Denmark as part of a multi-centre 
trial (Agati et al. 2001), showing equal efficiency to the conventional special blue 
lamp (Ebbesen et al. 2003). One of the newest devices for the treatment of jaundice of 
newborns utilises solid state lamps consisting of a number of light-emitting diodes 
(LED). The few reports available so far advocate its use and indicate equal or better 
efficiency in treating neonatal jaundice (Seidman et al. 2000, Vreman et al. 1998). 
Another device utilises a laser as the light source. The apparatus is claimed to shorten 
the course of treatment compared to the use of fluorescent lamps (Mostnikova et al. 
2000). A follow-up study of the children who underwent treatment has been 
conducted.
The administration of medications as an alternative to phototherapy is not widespread. 
In addition to the types of medications mentioned in paper 1 of this thesis, the 
elevation of bilirubin concentration in the case of neonatal isoimmunisation can be 
controlled by the use of intravenous immunoglobulin. Its use is still in the 
experimental phase (Rubaltelli et al. 1977, Rubaltelli 1998).
From a safety-point of view it has been unsatisfactory that phototherapy has been 
exempt of an operating guidance with respect to excessive radiation. In 2000 the 
International Electrotechnical Commission provided an international standard with 
particular requirements for the safety of infant phototherapy equipment (IEC 2000). 
The standard includes, among other topics, a section on protection against hazards 
from unwanted or excessive radiation as well as on accuracy of operating data and 
protection against hazardous output (measuring principles and uniformity of the 
irradiance). 
1.2.4 Adverse effects of phototherapy 
Paper 1 of this thesis addresses risk factors associated with the use of phototherapy. 
Additional information on and discussions of a number of biochemical (effects on 
melanin, light sensitive vitamins and haemolysis) and cellular in vitro effects
(cytotoxicity mechanisms, DNA damage and mutations) are found in papers 3-8. 
Therefore, only a brief presentation of side effects will be addressed in this paragraph. 
Short-term clinical effects 
The few reported clinical effects during the use of phototherapy are transient. One of 
the earliest reports on the issue mentions rash, diarrhoea and lethargy (John 1975). 
Increased insensible water loss during phototherapy has been described (Bell et al. 
1979, Oh and Karecki 1972, Wu and Hodgman 1974). However, newer studies link 
this observation to heat stress rather than irradiation (Kjartanson et al. 1992a, 1992b). 
Indeed, halogen lamps without proper filtering will emit infrared radiation and may 
cause undesired heating of the patients. Jährig et al. (1993a) reported increased body 
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temperature in 25 % of the cases where such lamps were used. The problem may be 
relevant in many hospitals since the occurrence of halogen lamps in neonatal intensive 
care units world-wide has been reported to be 25 % (based on 108 units) (Hansen 
1996).
A rare observation of light treated jaundiced newborns is the bronze baby syndrome 
(Kopelman et al. 1972). The patient develops a greyish-brownish tint as a result of the 
combination of hyperbilirubinaemia, cholestasis and an increased porphyrin 
concentration in serum. 
Long-term effects
The report by Wu et al. (1992) of increased frequency in sister chromatid exchanges 
of newborns with Down’s syndrome submitted to phototherapy has been confirmed 
both by a new study (Wu et al. 1996) and by a study on newborns without the 
chromosomal syndrome (Tsai et al. 1998). Sirota et al. (1999) found that phototherapy 
affected the function of the immune system in the newborn by altering the cytokine 
production.
1.3 Synopsis of the papers 
A short summary of the various papers with emphasis on the main results is given 
below. Throughout this thesis the word “paper” has been used equivalent to the word 
“chapter” when the eight chapters contained in the thesis are presented. In papers 3, 5 
and 8 the author of this thesis is responsible for the following parts: 
Paper 3: Interpreting the reflectance spectroscopic measurement data with respect to 
bilirubin and neonatal physiology. Description of the material concerning patients and 
phototherapy equipment) (Experimental, 2.2.1-2.2.4, except for the description of the 
instrument in 2.2.3). Writing most of the text concerning biological and physiological 
aspects. This paper will also be part of the doctoral thesis of Dr. ing. student Lise 
Lyngsnes Randeberg, NTNU. 
Paper 5: HPLC-methodology, experiments, computations, interpretation of results and 
describing the HPLC-technique in Materials and Methods (2.4). Performing the 
apoptosis experiments using the TUNEL-method (2.5). Participating in writing and 
revising the manuscript. 
Paper 8: Participating in decisions concerning the methodology, performing some of 
the experiments in the late phase of the experimental work and writing most of the 
first version of the paper. 
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Part I: Preparations for clinical phototherapy studies. 
Paper 1: Phototherapy of hyperbilirubinaemia in newborns; the need for a better 
treatment and follow-up. 
Ellen Bruzell Roll and Terje Christensen 
The original and abridged Norwegian version is published in the Norwegian Journal of Epidemiology 
1997;7 (1):93-8. Translation by the authors.
The paper points out the need for improvement and optimisation of phototherapy of 
jaundiced newborns based on current knowledge and previous studies. The planned 
clinical study, which is further described in papers 2 and 4, is presented. Furthermore, 
the need for long-term follow-up of the treated children, with particular emphasis on 
cancer development, is addressed. The aetiology of hyperbilirubinaemia is shortly 
presented, as well as possible adverse effects of the light treatment. Areas of 
improvement of phototherapy are described and cover the parameters wavelength, 
irradiance and fractionation treatment. The English version (paper 1) covers the 
additional topics of treatment devices and medications. 
Paper 2: Ethical aspects of clinical research involving children, exemplified by a 
research project on phototherapy of jaundice. 
Ellen Bruzell Roll and Terje Christensen 
The original Norwegian version is published in Barn 1997;2:29-45. Translation by Margaret F. 
Kallevig.
The paper was prepared to assess the ethical considerations essential in the planning 
and execution of any clinical study, in particular those involving children. The 
phototherapy optimisation study presented in paper 1 and further detailed in paper 4 is 
thoroughly examined in relation to the ethical guidelines and assessments addressed in 
the paper. The article raises questions on the necessity of the currently practiced 
ethical guidelines and legislation with respect to research on humans, particularly 
children. Furthermore, whether research on children is a benefit and whether it is 
inevitable, is discussed herein. Issues on risk concept, informed consent and its ethical 
implications are also addressed. 
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Part II: In vivo studies on jaundiced newborns. 
Paper 3: In vivo reflectance spectroscopy of jaundiced newborn skin reveals 
more than a bilirubin index. 
Lise Lyngsnes Randeberg, Ellen Bruzell Roll, Lill Tove Norvang Nilsen, Terje 
Christensen and Lars O. Svaasand  
Submitted to Acta Paediatrica 
Reflectance spectroscopy is a non-invasive technique used to assess skin optical 
parameters useful in the monitoring of neonatal hyperbilirubinaemia. The reflectance 
spectrum obtained is the basis for computations of a bilirubin index, which is 
correlated to serum bilirubin. Furthermore, analyses of the spectrum enable the 
assessment of other skin chromophores such as haemoglobin and melanin, and of 
processes such as bilirubin kinetics and skin changes observed during and after 
phototherapy. The paper presents reflectance measurements performed on a group of 
jaundiced and non-jaundiced newborns not subjected to phototherapy and on a group 
receiving the treatment. The melanin index was higher for the phototherapy group, 
indicating that pigmentation had occurred. The reflectance measurements 
strengthened previous arguments for choosing the forehead as a standard 
measurement site for determination of a transcutaneous bilirubin index. The findings 
of stagnation in serum bilirubin while the transcutaneous bilirubin index still 
increased during phototherapy, may aid in the monitoring of the rate of formation and 
deposition of bilirubin to avoid neurological damage in severe cases. 
Paper 4: The effect of phototherapy on light sensitive vitamins in the serum of 
jaundiced infants. 
Ellen Bruzell Roll 
Paper 4 is the second of the two papers based on in vivo examinations. The jaundiced 
newborn cohort is unique to the present study. The first two papers of this thesis 
introduce the clinical investigations presented in this study of various parameters 
influencing phototherapy and the study of adverse effects related to the irradiation. 
Further argumentation is given for optimised treatment based on inspection 
experience and international guidelines. The protocol for the planned and partly 
accomplished multi-centre study is presented. Blood samples from jaundiced 
newborns subjected to phototherapy of various durations were analysed for the light 
sensitive vitamins riboflavin (vitamin B2), two flavoenzymes and retinol (vitamin A). 
The serum riboflavin concentration decreased to half its pre-treatment value after few 
hours of phototherapy, whereas the flavin isoenzymes concentration remained 
constant. The retinol concentration even increased during phototherapy, indicating 
that supplementary vitamin was given to most of the infants in the study (most were 
recruited from intensive care units). 
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Part III: In vitro cell studies on adverse effects of phototherapy. 
Paper 5: Bilirubin- and light induced cell death in a murine lymphoma cell line. 
Terje Christensen, Ellen Bruzell Roll, Alicja Jaworska and Gunnar Kinn  
Published in the Journal of Photochemistry and Photobiology B:Biology 2000;58:170-4. First 
presented at the 2nd Internet Conference on Photochemistry and Photobiology at 
http://www.photobiology.com/photobiology99/  
The first in vitro article of this thesis presents preliminary results from the combined 
effects of bilirubin and (blue) phototherapy light on mouse lymphoma LY-R cells. A 
presentation is given of the cell line and its application in various radiation and cell 
toxicity studies. Different methods for scoring apoptosis after bilirubin and light-
treatment of the cells gave corresponding results and revealed that the cell toxic 
mechanism apoptosis, occurred early. Experiments performed under less than 
optimum conditions showed essentially no difference in apoptotic cell toxicity 
between fractionated and continuous irradiation of equal light dose (radiant exposure). 
High pressure liquid chromatography analyses of bilirubin solutions showed that the 
light doses causing death were able to photooxidise bilirubin significantly. 
Paper 6: Bilirubin induces apoptosis in the dark, and irrespective of irradiation 
regimen in mouse lymphoma cells in culture.
Ellen Bruzell Roll 
Submitted to Acta Paediatrica 
Paper 6 is a continuation and refinement of the previous cell toxicity study. 
Experimental conditions were improved to keep the background cell toxicity low. LY-
R cells were exposed to bilirubin and continuous or intermittent blue phototherapy 
light at a constant total dose (radiant exposure). The irradiances (I) were either given 
as I or I/3 every other hour (intermittent treatment) or as I/2 or I/6 (continuous 
treatment). The three lower irradiance levels were clinically relevant. Cells with 
bilirubin were also subjected to dark exposure for various durations and incubation 
times. Like paper 5, cell toxicity was determined by the detection of apoptosis (two 
methods) and necrosis (one method). There was found dose reciprocity of apoptotic 
cell death between intermittent and continuous irradiation after both the shorter 
incubation time applied in the previous paper and after longer. Necrosis, on the other 
hand, was more pronounced after intermittent treatment. Bilirubin dark toxicity was 
observed after various exposure conditions and incubation times, and was classified as 
both apoptotic and necrotic. The paper discusses the three different possible causes for 
cell toxicity; direct light effects, light-sensitising effects and dark effects. A 
theoretical explanation of the mechanism of dark toxicity by apoptosis is offered. 
Paper 7: Formation of photoproducts and cytotoxicity from bilirubin irradiated 
with turquoise and blue phototherapy light. 
Ellen Bruzell Roll and Terje Christensen 
Submitted to Acta Paediatrica 
In this study, LY-R cells were exposed to bilirubin and either turquoise or blue 
phototherapy light of equal and constant irradiance to determine any possible 
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differences in cell toxicity. The cell toxicity determination methods of the two 
previous papers were employed. In addition to apoptosis and necrosis, cell damage 
parameters, such as reduction of mitotic index and inhibited cell growth were 
observed. Cell suspensions, cell pellets and cell-free solutions were analysed by high 
pressure liquid chromatography (HPLC) after exposure to bilirubin and irradiation of 
turquoise or blue light to evaluate the formation of bilirubin photoisomers and the 
reduction in the native bilirubin. The turquoise lamp caused slightly less cellular 
damage than did the blue lamp. Evaluation of the HPLC analyses and absorption 
spectroscopy indicated that photooxidation of bilirubin was more prominent with blue 
light irradiation, which may explain the higher cell damage observed at this 
wavelength. Previously reported results of more geometric photoisomers formed by 
blue irradiation were confirmed. The photoisomer thought to be the most important 
for the bilirubin clearance, lumirubin, was formed in similar amounts after irradiation 
with either lamp colour. In the presence of human serum albumin, the bilirubin 
photoisomers were found to be formed less efficiently from bilirubin bound to cells 
than from bilirubin in solution  
Paper 8: Effects of bilirubin and blue light on the osmotic fragility and the 
haematoporphyrin-induced delayed photohaemolysis of erythrocytes and 
spherocytes.
Ellen Bruzell Roll, Terje Christensen and Odrun A. Gederaas 
Submitted to Acta Paediatrica 
In the last in vitro work of this thesis, normal and spherocytic red blood cells were 
employed as a test system to further study the combined effect of bilirubin and blue 
phototherapy light in terms of the cells’ relative resistance to haemolysis. The blood 
cells were subjected to tests of both osmotic fragility and haematoporphyrin-induced 
delayed haemolysis. The osmotic fragility method confirmed that unexposed 
spherocytes are more fragile than unexposed erythrocytes. However, normal red blood 
cells exposed to bilirubin and light showed an increased osmotic fragility in contrast 
to the exposed spherocytes. Delayed haemolysis was not observed in bilirubin-
exposed cells in the absence of haematoporphyrin irrespective of pre-irradiation with 
blue light. The presence of bilirubin increased the degree of delayed photohaemolysis 
of erythrocytes in a dose dependent manner. However, pre-treatment with blue light 
had no additional effect. On the other hand, the spherocytes not only showed an 
increase in the degree of photohaemolysis when exposed to bilirubin, they also 
succumbed to a significantly larger photohaemolytic effect of bilirubin when the cells 
were pre-irradiated with blue light. 
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1.4 General discussion and future work 
This thesis contains studies of theoretical and experimental nature. The experimental 
studies are performed both in vivo and in vitro. A general discussion is included in 
this section as more detailed discussions related to each topic are addressed in the 
following papers. 
Preparation for clinical investigations and in vivo studies 
The work constituting Parts I and II of this thesis is limited to overhead phototherapy 
irradiation for treatment of newborn hyperbilirubinaemic patients, although the results 
may apply to patient groups with liver enzyme defects such as in the Crigler-Najjar 
syndrome (Arias et al. 1969). Whenever the expression “blue phototherapy light” is 
used, referral is made to Philips 20W/52 fluorescent light tubes.  
Paper 1 of the thesis addresses the need for optimised phototherapy and describes 
which physical parameters should be studied. This theoretical work offers an update 
on current phototherapy practices at the time of publication. Follow-up studies of 
possible cancerous effects are also suggested. The stated need for follow-up studies of 
skin cell changes is actualised by the finding in paper 3 of increased melanin index 
after phototherapy. Paper 1 refers to an Australian study (Harrison et al. 1994) linking
a high number of naevi (moles) to a risk factor for development of malignant 
melanoma with UV radiation exposure being a promoter for the later development of 
the melanomas. If not carefully controlled, phototherapy lamps may contribute to UV 
exposure (Gies and Roy 1990). Dose limits of UV are given in an international 
standard (IEC 2000). The increased melanin index (paper 3) may be linked to the 
tanning processes, immediate pigment darkening and delayed tanning, which may be 
involved in the development of nevi.  
The clinical study presented in paper 4 was assessed with respect to ethical questions 
and existing ethical and legal guidelines in paper 2. It was concluded that the 
particular study does neither inflict any unacceptable risk to the patients nor does it 
raise any serious ethical problems. Furthermore, the study is found to conform to the 
restrictions of Norwegian legislation and the applicable guidelines. The clinical study 
was already approved by a national ethical committee at the time of writing. Of the 25 
patients enrolled during the recruitment period, the participating hospitals reported of 
one or two denied consents (hospital staff, personal communication). A problem of 
uniformity of ethical guidelines occurred during the preparations for the international 
multi-centre study (Agati et al. 2001), which was incorporated into the protocol 
presented in paper 4. The problem was solved by letting each participating country act 
in accordance with their national legislature and guidelines. 
The planned clinical study of paper 4 was partly accomplished. The information 
obtained from the few patients enrolled, however, was not enough to determine 
whether turquoise fluorescent lamps were superior to blue in the clearance of serum 
bilirubin. On the other hand, a simultaneously conducted clinical study by our 
collaborators in the multi-centre trial was able to produce a patient material of 
acceptable size (Ebbesen et al. 2003). The researchers concluded that the turquoise 
fluorescent lamp was equally or more efficient in reducing the serum bilirubin 
concentration. This finding was a confirmation of reports of Donzelli et al. (1995) that 
a turquoise phototherapy lamp with a similar spectral output shortened the duration of 
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phototherapy. The irradiance of this lamp was sufficient and comparable to that of 
blue lamps, unlike previously produced green lamps (Agati et al. 1996). Neither the 
lamp used in Donzelli’s study nor the one used in the multi-centre trial are fabricated 
commercially. A clinically important advantage of the turquoise lamp is the 
theoretically less harmful effect to the retina of the patients by a factor of four 
(Matthes et al. 1999). It may also be speculated that the turquoise light with emission 
peak of 490 nm could have less photodegrading effect on riboflavin than blue light 
with an emission peak of 450 nm being almost identical to the absorbance peak of 
riboflavin (447 nm) as discussed in paper 4. Furthermore, many other endogenous 
molecules such as porphyrines, vitamins, aromatic amino acids and melanin absorb 
more strongly in the violet/blue part of the spectrum than at longer wavelengths. 
The obtained patient material of paper 4 was inadequate to determine an optimum 
irradiance level for blue light phototherapy of newborns. According to Tan (1977), 
there exists a threshold for the irradiance at which there is equilibrium between 
bilirubin destruction and formation of new bilirubin or transport of ZZ-bilirubin to the 
skin. He found that no further effect of phototherapy was seen above levels of 1-2 
mW/cm2 (Tan 1982). In paper 3, a point of discussion is the uneven distribution of 
irradiance emitted to the various body parts of the newborn when receiving 
phototherapy by a “light bed” and in different distances from an overhead light 
source. The irradiance received from the “light bed” varied by a factor five from 
shoulder to toe of the patient. In addition, the irradiance received by a conventional 
overhead phototherapy device varied by a factor three throughout the front body skin 
surface (Bruzell Roll, unpublished results). 
Radiometric definitions 
The term “light intensity” of a lamp is often confused with irradiance. Throughout this 
thesis the term “irradiance” is used to denote the light effect reaching a unit area and 
is more precisely defined as “the radiant flux per unit area in a specified surface that is 
incident on, passing through, or emerging from a point in the specified surface. The 
defining equation for irradiance, I, is
I = dĭ/ds,
where dĭ is an element of radiant flux and ds is an element of area in the surface”. 
The unit of irradiance is W/m2 (McCluney 1994). The concept of fluence rate is based 
on the definition of an area being the cross section of a sphere on which the radiation 
is incident at the point under consideration (Matthes et al. 1999). The term fluence 
rate is used instead of irradiance in the cell culture studies of paper 5. The term can be 
used interchangeably with irradiance when none or minute light scattering of the 
incident light is assumed and the radiation comes from one direction. 
All measurements of irradiance were performed with a radiometer (United Detector 
Technology 371, Hawthorn, CA). To determine the irradiance of the blue fluorescent 
tubes the photodiode probe 268Blue was used. This probe has a cosine angular 
response, i.e.,
Imeasured = Inormal × cos ș,
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where ș is the angle between the surface of the detector and the incident direction of 
the radiation (within values of ș of about 60°). The narrow spectral response of the 
probe has a peak sensitivity at 450 nm and overlaps the absorbance spectrum of 
bilirubin. The total light dose of irradiance over time is called radiant exposure, H, 
and is given by the following relationship: 
H = I(t)dt,
or in the case of constant irradiance which is the case in this thesis: 
H = I × t. 
In the cell culture studies of paper 5, the term fluence (= fluence rate × t) is used to 
express the dose.
Although two patient groups were subjected to fractionated and continuous 
phototherapy in the clinical study outlined in paper 4, other parameters were 
simultaneously varied and, thus, no conclusions could be drawn. Furthermore, the 
number of patients enrolled in the study was limited. Discussion of and the basis for 
fractionated treatment are offered in papers 1, 2 and 4-6. The choice of using light : 
dark periods of 1 : 1 h in the clinical study was based on findings by Berck et al. 
(1985) and Jährig et al. (1985) who recommended this cycle as the optimum. 
In paper 4 the blue light phototherapy effect on the light-sensitive vitamins riboflavin 
(vitamin B2) and retinol (vitamin A) in the serum of jaundiced patients was elucidated. 
The possible influence of wavelength, irradiance and fractionation regimens were not 
taken into consideration. The serum riboflavin concentration decreased to half the 
mean pre-treatment concentration after 7 h of phototherapy. This finding is a 
confirmation of previously reported results by Sisson et al. (1976) and Gromisch et al. 
(1977), although they reported on a reduction in the whole blood riboflavin 
concentration with less decrease and after a longer duration of phototherapy. The 
concentrations of the coenzyme derivatives of riboflavin, flavin adenine dinucleotide 
(FAD) and flavin mononucleotide (FMN), although highly sensitive to light, stayed 
constant throughout 31 h of phototherapy (paper 4). The serum retinol concentration 
did not decrease during phototherapy. The retinol values of the newborns in the 
intensive care units were higher than those of the newborns in the well-baby nursery. 
The finding that the riboflavin coenzymes and retinol concentrations stay relatively 
constant has not been previously published.
The results presented in paper 3 are, like paper 4, based on a cohort of neonates with 
hyperbilirubinaemia, of which a part was subjected to phototherapy. The patient 
material of paper 3 was collected in the fall of 1996. The results of reflectance 
spectroscopic measurements performed on the neonates were published in a post-
graduate thesis (Schmedling 1996) and later in a doctoral thesis (Spott 1999). The 
results presented in paper 3 are refinements of the algorithms and grouping of the 
material. New information has been extracted from the original data. The average 
melanin absorption coefficient, but not the erythema index, was increased for the 
group subjected to phototherapy compared with the non-treatment group. Tan (1989) 
describes findings of erythema and skin hardening (tanning) during blue and green 
light phototherapy. The phototherapy duration of his studies, however, was 300 h 
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compared to generally 24-48 h in the material presented in paper 3. Leaving out the 
group receiving phototherapy, the correlation of serum bilirubin to the reflectance 
spectroscopy based bilirubin index previously obtained by Spott, became weaker. A 
device for measuring transcutaneous bilirubin based on reflectance spectroscopy 
technology showed a better correlation (Bhutani et al. 2000). However, neither the 
size and composition of the newborn cohort nor the serum analysis method can be 
compared to our study. 
In vitro studies 
Part III, including papers 5-8, is dedicated to adverse effects of the combination of 
bilirubin and phototherapy in vitro. The three first papers concentrate on cytotoxic 
effects on the mouse lymphoma cell line, L5178Y-R. This cell line is extensively 
characterised with respect to various types of radiation, oxidants and other factors that 
may influence radiation sensitivity. It is found to be relatively sensitive to ultraviolet 
radiation (Beer et al. 1983, Godar and Lucas 1995, Separovic et al. 1997). 
Apoptosis caused by bilirubin in the dark was observed with four different methods in 
papers 5-7, and confirmation by a fifth method (DNA ladder technique) has been 
published previously (Roll 1999a). In all studies, early induction of apoptosis was 
demonstrated. In paper 7, an increase in apoptotic score was seen after 48 h 
incubation compared to 2 and 18 h. A concentration-dependent early induction of 
apoptosis and otherwise late apoptosis was observed in studies using bovine 
endothelial cells (no light exposure) (Tibbs et al. 2000). Studies of rat neural cells 
using half or less the bilirubin concentration showed early apoptosis (4 h) with a 
further increase after 16 h (Silva et al. 2001). In the first cell toxicity study, paper 5, 
similar fractions of the cells succumbed to necrosis and apoptosis in the dark, whereas 
in papers 6 and 7 necrosis was more pronounced. Compared with the later work, the 
apoptotic fractions of the first paper were higher as a result of using the less nutritious 
phosphate buffered saline (PBS) as exposure medium instead of cell medium, as used 
in the later studies. Paper 6 showed an increase in the number of apoptotic cells after 
longer dark exposures as measured by two separate methods, whereas the number of 
necrotic cells was more unaffected by the longer exposure time. 
When combining bilirubin and phototherapy light, early apoptosis was demonstrated. 
A much higher increase in apoptosis was seen 48 h after combined bilirubin and light 
exposure than after exposure to bilirubin in the dark. A higher fraction of cells were 
dying from necrosis in the studies of papers 6 and 7 than in paper 5, probably due to 
improved exposure conditions. Both necrosis (papers 6 and 7) and apoptosis (paper 7) 
increased with increasing radiant exposure. 
Cell toxicity effects observed after the exposure of the combination of bilirubin and 
phototherapy fractionation were investigated in papers 5 and 6. Although PBS was 
used as exposure medium in paper 5, similar conclusions were reached in the two 
papers: there was no difference in apoptotic score between continuous and 
intermittent irradiation at constant and clinically relevant radiant exposure. A previous 
in vitro study investigating the formation of photoisomers after fractionated and 
continuous irradiation of cell-free bilirubin solutions concluded that similar amounts 
were obtained after either irradiation regimen (Roll and Christensen 1999b). The 
tendency of a higher apoptotic score after bilirubin-incubated fractionated irradiation 
seen in paper 5 was not confirmed in the later study. On the other hand, the later work 
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showed that necrosis was more pronounced after bilirubin-incubated fractionated 
irradiation of lower irradiance and longer duration (same radiant exposure). Still 
keeping the radiant exposure constant, apoptosis increased when the bilirubin-treated 
cells received light at lower irradiances lasting longer compared with higher 
irradiance for shorter times irrespective, of fractionation. If clinically applicable, this 
observation implies that the phototherapy should be administered with sufficient 
irradiance to cause a relatively rapid effect instead of lowering the irradiance resulting 
in longer phototherapy duration. 
In paper 7, the non-commercial lamp emitting turquoise light described in the clinical 
work of paper 4 was compared to blue phototherapy light in identifying possible 
cytotoxic effects at constant and equal irradiance. The turquoise light caused less 
cellular damage than did the blue light both in terms of cell toxicity and cell growth. 
These findings support earlier observations by Sideris et al. (1981), Rosenstein et al. 
(1983) and Christensen et al. (1988) among others who reported of in vitro side
effects of blue light. A clinically inclined reason for choosing a longer wavelength 
lamp is the increase in the formation of the therapeutically efficient photoisomer 
lumirubin (Onishi et al. 1986) with increasing wavelength. The study of paper 7 
concludes that the formation of lumirubin is similar after exposure to either blue or 
turquoise light. 
Papers 5 and 7 confirm previous findings by our group (Christensen 1986, 
Christensen et al. 1988, Christensen and Kinn 1993) that phototoxicity is more 
pronounced after light doses that cause photooxidation of bilirubin. The earlier 
findings by Christensen (1986, 1988) and Rosenstein et al. (1983), together with the 
results presented in papers 5 and 7, indicate that cell death is preceded by hydrogen 
peroxide production in the cells and in the medium. Studies performed by McDonagh 
(1971) indicated formation of singlet oxygen, although of low quantum yield (Sloper 
and Truscott 1982). In a previous set of experiments we found that the amount of 
singlet oxygen was below the detection limit of an infrared spectroscopic method 
(Roll et al. 2001).
Phototoxicity of bilirubin may also be aggravated by sensitisation of endogenous 
compounds, such as riboflavin, as discussed in paper 4, and porphyrins, which were 
studied in relation to erythrocytes and spherocytes in paper 8. This paper confirms 
previous in vitro results of increased fragility of erythrocytes exposed to bilirubin and 
light (Odell et al. 1972), but this effect has not been confirmed in vivo (Alpert et al. 
1984). When sensitised by porphyrin, only spherocytes show an increased fragility 
with increasing light dose, indicating that phototherapy may increase haemolysis in 
jaundiced newborns with hereditary spherocytosis. 
Future work 
To further approach the optimisation of phototherapy of hyperbilirubinaemic
neonates, more clinical studies should be undertaken with focus on the physical 
parameters investigated in this thesis. The protocol for such investigations has been 
worked out for the future (paper 4). Clinical results from the use of a new lamp colour 
have been published, and more results are under way. Follow-up examinations on the 
development of nevi after phototherapy treatment should also be carried out. In vitro
phototherapy studies should focus on the formation of reactive oxygen species and the 
mechanisms leading to cell damage and death. 
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SUMMARY
Treating jaundiced newborns with artificial light has been done for the last three decades
without substantial improvements of the method. It can be estimated that between five and 10 
% of all newborns receive phototherapy. The standard treatment is the use of artificial, visible 
light sources for many hours up to several days. The wavelength and intensity of the light are 
factors influencing the effect of the treatment, however, the risk for long-term side effects
should be considered. The results of the treatment need more thorough investigation for two 
purposes; to evaluate the therapeutic efficiency and to look for potential side effects.
Furthermore, recognition of side effects may take more time than three decades. Follow-up
studies have raised the question whether these study-periods are sufficiently long and whether 
a clear distinction between the effects of the light itself and the neurotoxic effects of bilirubin
have been made. The aim of our experimental and clinical investigations is to optimise the
phototherapy, particularly with respect to light intensity and wavelength. Our epidemiological
work will address long- term side effects of phototherapy, particularly in relation to cancer
development (lymphocytic leukaemia and malignant melanoma).
1.1 INTRODUCTION
The beneficial effect of light on the condition of hyperbilirubinaemia was discovered by an
observant nurse in 1956.  The observation was done when infants were exposed to normal
daylight. Very soon artificial light sources were applied for treatment, and the use of
phototherapy spread rapidly after the discovery of Cremer, Perryman and Richards (1). Today
it is estimated that 5 - 10 % of all newborns in many countries are given phototherapy for
longer or shorter times during the first days of their lives (2, 3). Thus, the total number of
persons that have been treated to this day is probably several millions, but there have been no
systematic registrations of the total number in any countries. Furthermore, the number of
patients undergoing treatment varies with time and with the use of different indications for
treatment in various hospitals. A discussion of these aspects can be found elsewhere in this
volume (2).
Since the discovery of phototherapy only few improvements in the methodology have been
made. Still, the standard treatment is the use of artificial light sources placed at a certain
distance from the infant. More modern approaches have been introduced, however, and will be 
mentioned later in this paper. We do not intend to describe the treatment in detail since general 
descriptions may be found in several books and journals (e.g. 3-6).
Bilirubin is a tetrapyrrole which is a break-down product of several haemoproteins, although
quantitatively the breakdown of haemoglobin plays the dominant role. More than half of all
newborns show signs of transient jaundice occurring a few days after birth. There are several
reasons for the typical unconjugated hyperbilirubinaemia in newborns. Prenatally the bilirubin is 
excreted by the mother, and it is believed that the unconjugated bilirubin, being an unpolar
substance, can easily cross the placenta. Postnatally the infant must take up the adult
mechanism where glucuronic acid residues are coupled to bilirubin to form water soluble
bilirubin diglucoronide. The liver enzyme glucoronyltransferase is induced at birth, but its
activity is frequently insufficient to conjugate the heavy load of bilirubin occurring due to the
rapid turnover of haeme early in life. Several pathological conditions may aggravate the
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problem. When unconjugated bilirubin is present in plasma it is normally transported bound to 
albumin and lipoproteins and the tissue concentration is relatively low. At higher
concentrations or if the binding capacity is low the concentration of free bilirubin may increase 
and the bilirubin may be taken up by other organs, probably mainly as free bilirubin in the form 
of a mono-anion (7). This process may lead to cytotoxicity, notably in the brain (4, 8). In
serious cases the bilirubin will stain certain parts of the brain and the binding is manifested as 
so-called kernicterus.
Before the introduction of phototherapy the only treatment of severe hyperbilirubinaemia was 
exchange transfusion, however, this procedure is performed only rarely today. Normally, white 
or blue light is delivered to the skin of the infant with a relatively high irradiance, ranging from 
below 0.5 mW/cm2 to more than 2 mW/cm2, but the light intensity is seldom measured (9). The 
light penetrates through the epidermis and is absorbed in the skin or vasculature by bilirubin
and other substances. The spectrum of the light is changed on its way through the tissue, and 
therefore, the more penetrating, longer wavelengths will play a more important role for effects 
on bilirubin deeper in the tissue (10). The total dose of light is dependent on the duration of
treatment and is often expressed as hours of phototherapy, although the physically correct
expression should be J/cm2 or an equivalent unit for light energy. Therefore, it is not
straightforward to evaluate the irradiation conditions and their potential therapeutic or adverse 
effects.
The absorption of light in bilirubin leads to several photochemical reactions in the molecule
(see (11) for a review). Probably, the reaction which is mainly responsible for the therapeutic
effect is the formation of structural photoisomers being more water soluble than bilirubin itself.
Photooxidation of bilirubin, on the other hand, has been suggested as a mechanism that may
lead to unwanted side effects (12-14).
The aim of this article is to suggest areas where the therapeutic effect of light may be improved 
in the future, particularly with respect to light irradiation regimens. The results of the treatment 
should be followed closely, in order to score both the results of reduced hyperbilirubinaemia
and potential side effects. Although a number of follow-up studies have been performed,
phototherapy was introduced relatively recently and there may still be effects that have not yet 
been recognised.
1.2 EVALUATION OF RISK FACTORS AND PREVIOUS FOLLOW-UP STUDIES
The risk of brain toxicity is the reason for treating hyperbilirubinaemia (8, 15). Several follow-
up studies have reported on the association between high bilirubin concentrations and different 
neurological symptoms (see (4, 5, 16) for reviews), but few have been able to demonstrate a
clear relationship between phototherapy and a reduced risk of brain toxicity. A different
question is whether light treatment may be a risk factor. If so, one should probably look for
different types of effects than the classical bilirubin-induced brain damage.
Light may interact directly with molecules in the tissue. The absorption is generally very
dependent on the absorbing molecules. Ultraviolet (UV) radiation has been regarded as the
biologically most active type of optical radiation because it is absorbed in the DNA and may
form photochemical changes in many other biomolecules. The amount of UV radiation in
phototherapy lamps is probably very small in most types of equipment (17). The biological
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effect of longer wavelength light, present in higher amounts in phototherapy lamps has been
studied. Several molecules may absorb in the relevant wavelengths (Table 1) and particularly
porphyrins, vitamins, amino acids and bilirubin have been discussed as important light
absorbers. Ben-Sasson and Davis (18) hypothesised that an observed increased incidence of
acute lymphocytic leukaemia could be partly due to the use of phototherapy in hospitals.
Findings of van Steensel-Moll and co-workers in the Dutch Childhood Leukaemia Study
Group (19) supported this hypothesis. Photoactivation of endogenous protoporphyrin was
suggested as the carcinogenic mechanism. However, the finding that bilirubin is a
photosensitiser capable of inducing DNA damage and mutations in vitro (12-14, 20) indicates
that bilirubin may play a role as well because of its presence in much higher concentrations in 
newborns and its higher blue light absorption than protoporphyrin. In our work with in vitro
photoeffects of bilirubin it has been shown that bilirubin can produce photoproducts with
relatively long lifetimes. Therefore, these products may diffuse from the site of formation to 
other organs. Rosenstein and colleagues (12) showed that H2O2 (hydrogen peroxide) was
formed upon irradiation of bilirubin together with other unidentified photoproducts. These
products may be organic peroxides (14) or results of light induced cross-linking between
bilirubin and other biomolecules (21). It is interesting to notice that photochemical formation
of H2O2 also is known to take place in parenteral solutions containing riboflavin and amino
acids when exposed to phototherapy lamps (22).
It has been debated whether phototherapy can lead to long lasting clinical side effects. In a
study of the frequency of sister chromatid exchanges it was concluded that in genetically
normal infants the therapy did not increase the frequency. Nevertheless, a significant increase in 
the frequency was found in infants with Down’s syndrome (23). Among other important topics 
are eye damage (24-26), depletion of essential nutrients (vitamins and amino acids) and a
number of short-term clinical side effects (27). Psycho-social effects on the relationship
between parents and the infant due to separation during long-lasting phototherapy have been
indicated as a side effect that should be taken into consideration (28).
1.3 AREAS OF IMPROVEMENTS
Despite the high number of newborns receiving phototherapy and the 30 years of experience
with this form of treatment there is still need for improvements and optimisation.
The manner in which the phototherapy is «administered» to the hyperbilirubinaemic newborns 
vary internationally as well as nationally. Criteria for treatment are set up and followed within 
hospitals, but vary between them, and are currently heavily debated. (See (2)). The thorough
work of some researchers has led to a better understanding of the effect of phototherapy (5), 
but there is still no standardisation with respect to irradiance, wavelength, fractionation and
type of equipment. Thus, there is no consistency in the treatment given to certain groups of
jaundiced newborns.
1.3.1 Irradiance
Irradiance is defined as the power of light reaching a unit area, often expressed in mW/cm2.
Multiplied by the duration of irradiation the radiant exposure (J/cm2) is obtained, of which the 
photoeffect is a function. There is assumed to exist an optimum irradiance energy in
phototherapy of jaundiced newborns where a further increase above this value induces
photoconversion of bilirubin less efficiently (29, 30). Likewise, there exists a threshold dose for 
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the irradiance at which there is equilibrium between bilirubin destruction and formation of new 
bilirubin (30). In Tan’s work there was no further effect of phototherapy above levels of 1-2
mW/cm2 (31). In spite of this knowledge we have found levels of irradiance below and above
this irradiance range in Norwegian hospitals (9). 
A common error in reporting irradiance values in the literature is the lack of specifying the
band width of irradiance. The value is often given in µW/cm2 ⋅nm leaving it to the reader’s
guesswork to find the total irradiance. Attempts are made to give irradiance values in mW/cm2
from radiometer measurements, but often leaving out information on the spectral sensitivity of 
the probe used. This inconsistency makes it complicated to compare various types of
equipment and more importantly, to determine the total light dose (radiant exposure) received 
by the patient. The total duration of the phototherapy is not recorded at most hospitals, also 
contributing to the unknown light dose uncertainty.
1.3.2 Wavelength
The wavelength of the light source is another variable factor in the phototherapy treatment of
hyperbilirubinaemia. White and blue light is most commonly used, the blue light being thought
to match the peak of the bilirubin absorption spectrum more closely. Unfortunately, we have
also indications that daylight-simulating fluorescent tubes, emitting wavelengths in the UV
region, have been used in phototherapy.
The use of blue versus green or blue-green lamps is still a subject of controversy (32-37).
There are several factors favouring the longer wavelength lamps, taking into account not only
the absorption of bilirubin, but also the formation of the more water soluble photoproduct,
lumirubin, which has an increase in quantum yield in the green wavelength region (38, 39).
Also, there is a shift in the bilirubin absorption in this part of the spectrum in vivo due to skin 
constituents and the binding of fatty acids to albumin (40, 41). A third factor favouring green 
light is that due to lower absorption coefficients of the main skin pigments in this part of the
spectrum green wavelengths reach deeper into the skin tissue than do the blue wavelengths
(Table 1). In vitro studies of cells in the presence of bilirubin and light show the largest cellular 
effects (cell death, mutations and DNA damage) at 450 nm (blue) (42). Also worth mentioning 
in this respect is the research done by Setlow’s group on the melanoma induction of the fish
Xiphophorus. The group found that UVA radiation induced melanomas most efficiently and
furthermore, that visible light as well was capable of induction of melanomas in that particular 
fish model (43).
It is important to note that in comparing lamps the difference in spectral irradiance for all
wavelengths must be considered. Some clinicians have found that the duration of phototherapy 
was significantly shorter using blue lamps (observing, however, less phototherapy rebound for 
the green light treatment) (44), but this fact may be attributed to the lower irradiance of the
green lamp, not to the wavelength itself. Pratesi’s group in Italy has introduced a new blue-
green phototherapy lamp which proves to be more efficient compared to a special-blue lamp
(45). Further testing, also in vitro, of this blue-green lamp, is now being carried out by our
group in Norway.
1.3.3 Fractionation
It is known that the effectiveness of irradiation depends exponentially on the initial bilirubin
concentration (5). During an interruption of phototherapy a rebound of bilirubin into the skin
occurs, improving the effectiveness of continued treatment. From an energy dose viewpoint
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fractionation of the treatment will be advantageous to a continuous treatment. Even though the 
intermittent phototherapy increases the time before a certain lowering of bilirubin is achieved
the total light dose to the patient would be less (5). Jährig et al. recommend an optimal form of 
treatment as light : dark periods of 1 : 1 hours (accompanied by regular position changes of the 
infant) (5).
There are other factors favouring intermittent phototherapy aside from the lower energy dose 
to the newborn. The dark periods both give the parents better opportunity to closeness with
their baby and it makes nursing easier. It is our opinion that the fractionation regimen
recommended by Jährig et al. is not widely followed in Norwegian hospitals.  The infants
receiving phototherapy are taken out of the light for nursing and diapering «now and then»
without control of the time spent outside the phototherapy unit.
1.3.4 New equipment
During the past seven years three new phototherapy equipments have arrived on the market.
Two of these apply a similar principle; the fiberoptic blanket, which can be wrapped around the 
jaundiced infant or the infant can be laid directly onto it. Compared to conventional
phototherapy, the use of the blanket device improves the contact between baby and parents.
The «Bili-bed», on the other hand, consisting of a single fluorescent lamp, illuminates the infant 
through a transparent mattress. Measurements of this latter unit earlier this year led us to
conclude that the «Bili-bed» gives relatively high irradiance values (3.1-3.5 mW/cm2) locally
on the mattress, but the irradiance varied from less than 0.5 to 3.5 mW/cm2 throughout the
bed area (Roll and Christensen, unpublished results). A «Biliblanket» had a relatively
homogenous irradiance between 1.4 and 2.1 mW/cm2, although the measurement involved
several technical difficulties (UDT-detector 371, probe «268 BLUE») (9).
It is our impression that these types of equipment are not being used in Norwegian hospitals
for treatment of the higher bilirubin values due to the paediatricians’ experience that the light-
bed and -blanket are less efficient than conventional phototherapy. 
High intensity double-surface phototherapy on a fluid bed has been reported (46, 47)
concluding that this form of treatment is more effective in reducing bilirubin than conventional 
phototherapy. The authors recommend this high intensity therapy during critical periods of
hyperbilirubinaemia demanding rapid control of the condition.
1.3.5 Medication
There are two major types of medication in use for the control of hyperbilirubinaemia, both of 
which may be combined with phototherapy. Medication is given shortly after birth. The first 
medication induces the synthesis of bilirubin conjugating enzyme (uridine-diphosphate
glucoronyl transferase) and of the ligandin (the hepatic transport protein). Substances used for 
this purpose are mainly the barbiturates phenobarbitone and methylphenobarbitone, but also
nikethamide (48, 49). The second type of medication is based on pharmacological inhibition of 
haeme oxygenase, thereby limiting the formation of new bilirubin. The drug used is
metalloporphyrin (50, 51), some of which may have a photosensitising effect (Christensen and 
Kinn, unpublished results)*.
In addition, several inert absorbents have been tried with the capacity to bind bilirubin in the
intestinal lumen. Agar, charcoal and cholestyramine have all been administered with varying
URN:NBN:no-7250
1 - 7
success, although the combination with phototherapy improves the therapeutic outcome (52,
53).
The need for optimisation of the physical parameters of phototherapy is perhaps even more
urgent as the trend towards a later treatment onset is advocated in several hospitals. A
jaundiced infant who is allowed high bilirubin values will be at increased risk if submitted to a 
treatment regimen of imprecise character due to lack of control of irradiance and duration and 
a suboptimum wavelength. George (54) concluded in his article that perhaps more attention
should be drawn to intensity instead of colour. We would like to add that more attention
should be drawn to physics in general.
*Christensen T, Kinn, G, Reitan J B. Photosensitizing effects of metalloporphyrins in connection with
hyperbilirubinemia. First Internet Conference on Photochemistry and Photobiology, Internet Journal of
Science, Biological Chemistry, 1997(3). http://www.photobiology.com/v1/contrib.htm
1.4 WHAT TO LOOK FOR IN EPIDEMIOLOGICAL STUDIES
In a follow-up study three years after phototherapy Valkeakari and coworkers (55) found no 
differences between the phototherapy group and the control group when a number of clinical
and biochemical parameters were compared. The same trend can be found in a number of other 
follow-up studies. These findings seem reassuring, but it is pertinent to inquire into whether the 
previous studies focused on the relevant parameters of phototherapy or whether the follow-up
periods have been sufficiently long to reveal possible side effects of the treatment. The first law 
of photobiology states that only absorbed light can have a biological effect. Therefore, a first
approach will be to look for effects in light accessible organs, first of all in the skin and the
eyes. Transport of photoproducts from the light exposed field to other organs may also take
place, and the blood may be exposed to a certain degree in the capillaries of the dermis. On this
background one may expect both local and systemic effects, but it is important to be able to 
separate effects of light and effects of bilirubin toxicity.
Increased incidence of cancer is a possible effect in persons treated with light as newborns. In
this respect we have established a cooperation project with the Medical Birth Registry in
Bergen with the aim to match their register with the Norwegian Cancer Registry. After 1985 
the information on the use of phototherapy has been collected systematically by the birth
registry. We have applied for funds to establish a cohort of phototherapy treated persons
between 1967 and 1985 from a group of more than 10 000 persons reported with
hyperbilirubinaemia during this period. The studies of cancer in general are interesting, but it is 
our hope to be able to put particular emphasis on lesions in the skin and to test the hypothesis 
of Ben-Sasson and Davis (18) that phototherapy can lead to increased risk of acute
lymphocytic leukaemia.
Other skin diseases and conditions are also of interest. It has been shown that the number of
pigmented moles (nevi) at early age is influenced by UV irradiation, (56) and we are interested 
in testing whether the number of nevi may be increased by phototherapy. If so, this finding
could indicate a higher risk of melanoma at older age, since a high number of nevi is a risk
factor for development of malignant melanoma (with UV radiation exposure being a promoter
for the later development of the melanomas) (57).
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As mentioned earlier, eye damage from phototherapy light is clearly a possibility if the eyes are 
not properly shielded, but we would hesitate to regard this as a general problem for the
children exposed to phototherapy. To reduce the risk of eye damage, the evaluation of cases
where the eye shields have not been used properly should be done on an individual basis. Of
course, it should be stressed that eye protection must be applied on all infants undergoing
conventional phototherapy.
Finally, it is desirable to evaluate different phototherapy intensities and different wavelengths in 
the future, but at present the records of these parameters are too weak to assign individual
infants to specific treatment categories.
Molecule Main absorption wavelengths Biological effect
Endogenous
Porphyrins UVA and visible Photosensitisation by singlet
oxygen
Vitamins (Riboflavin) UVA and blue Formation of hydrogen
peroxide and other peroxides
Aromatic amino acids UVB and UVA Lost function, photosensitistion
UV and visible Photoprotection,
photosensitistion
Photosensitisation (may also
act as anti-oxidant)
Melanin
Bilirubin
Exogenous
Drugs (e.g. tetracyclins,
psoralens from plants)
Blue
All optical wavelengths Photoallergy and -toxicity
Table 1. Some light absorbing molecules and probable biological effects of light absorption.
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2.1 INTRODUCTION  
Researchers without previous clinical experience are confronted by many ethical 
considerations when initiating a project which involves newborn human test subjects. A 
number of guidelines exist for research involving children, but these are not necessarily in 
complete agreement with each other. We will in the following article discuss the need for 
ethical guidelines in general, and for research on children in particular. Questions concerning 
research justification, risk factors involved and informed consent will be elucidated. The 
present research project, which aims to improve phototherapy of newborns with jaundice, will 
be described. The ethical considerations with regard to the research protocol will be pointed 
out, and the project will be discussed in relation to some basic issues which seem relevant for 
clinical research involving children. 
2.2 THE NEED FOR ETHICAL GUIDELINES 
Aside from the fact that the research in itself must be justifiable, it is also important that the 
correct type of research is chosen and that it is conducted according to ethically acceptable 
principles.
The so-called descriptive normative systems for ethics are usually divided into two main 
groups (Kragh and Pedersen 1991): Consequence ethics and deontic ethics. The consequential 
theory is that an action is morally correct if it leads to the best possible result – “benefit 
greater than harm”. Thus, in medical research one must assess what benefit (i.e., alleviation of 
pain or improved life-quality) a certain project will have for the research patients and future 
patients, and if this benefit will be passed on to all patient groups. 
Justification and freedom are the main principles in deontic ethics. A deontic theory 
central to the existent guidelines for medical research, is individual autonomy. According to 
the philosopher Emmanuel Kant, individual autonomy is a necessary attribute for a free-
acting person and should, therefore, be respected without reservation. 
The need for ethical guidelines has increased due to the fact that research in general has 
achieved a far larger scope. New technology is constantly being introduced, and mankind has 
experienced that research can also be used to the researchers’ advantage and carried out in a 
blameworthy manner. The demand for ethical guidelines played a prominent part in the 
Nuremberg Proceedings after the Second World War. The Nuremberg Code was drafted in 
1947 in response to this demand. An attempt was, thereby, made to formulate the basic 
conditions for which medical-scientific experiments using human subjects is ethically 
justifiable (Rossel 1985). The Declaration of Helsinki was first composed in 1964, and later 
revised in 1975 and 1983 (Declaration of Helsinki 1983, Riis 1985). This declaration aims to 
regulate the ethical aspects of research in an international context, “in agreement with 
science’s boundless forms for collaboration and exchange of information”. The Declaration of 
Helsinki applies both deontic ethics and consequence ethics. An example of consequence 
ethics is the references to the research subjects’ safety, while an example of deontology is 
found in the Declaration’s Part III, paragraph 4: “In research on man, the interest of science 
and society should never take precedence over considerations related to the wellbeing of the 
subject”. The Declaration has evolved from a comparatively general recording of ethical 
principles in the form of imagined situations or research projects. Naturally, it can neither 
cover all situations and projects, nor all patient groups. Furthermore, it is not binding in a 
Norwegian court of law. Thus, on basis of the Declaration of Helsinki, one is provided with 
some national guidelines for certain areas within medical research. 
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2.3 GUIDELINES FOR RESEARCH INVOLVING CHILDREN 
Similar to research with humans, research with animals undoubtedly raises ethical problems. 
Ethical guidelines for the use of test animals are legalized (Act concerning the welfare of 
animals of 20.12.1974, Regulations for biological experiments with animals, Norwegian 
Department of Agriculture 22.12.1977), and the Law for medical use of biotechnology of 
1.9.1994). On the other hand, humans used as test objects have a very weak position in 
Norwegian law. Test activities are based on voluntary participation, grounded on respect for 
personal integrity. Thus, one is protected to a certain extent by criminal laws’ paragraphs 
concerning bodily damage, illegal force, deprivation of freedom and consent (The General 
Civil Penal Code, paragraphs 229, 231, 222, 223, 235 (subclause 2). There are also laws that 
provide advice on what is permissible, such as the Law for Doctors (19.06.69) and the 
Hospital Law of 13.06.80 (doctor’s professional secrecy and journal instructions). 
Furthermore, regulations exist for limited areas (clinical trials, research in psychiatric 
institutions and research on the mentally handicapped), but supplementary guidelines are 
absolutely necessary to protect the test patients as much as possible. These guidelines are 
especially important for test persons who are minors, unconscious, mentally retarded, 
mentally disturbed or senile (Riis 1985). 
As test persons, children are an exposed group for several reasons. They are 
psychologically and physically less robust than adults. They are physiologically more 
vulnerable, since they are still growing, and the risk of future complications is greater. 
Furthermore, the youngest groups do not have the prerequisites to understand what it may 
imply to be a test subject. 
The Declaration of Helsinki indirectly opens for research involving children in Part I, 
paragraph 11, which deals with informed consent from a legally authorized representative. On 
the other hand, there is no direct encouragement. In 1982 the World Health Organization 
(WHO) in collaboration with the Council of International Organizations of Medical Sciences 
(CIOMS) prepared a set of guidelines which elaborates certain points in the Declaration of 
Helsinki (Proposed International Guidelines for Biomedical Research Involving Human 
Subjects. CIOMS, Geneva, 1982). In one chapter concerning informed consent, there is a 
separate section dealing with children. Here it is pointed out that research on children should 
not be performed if similar research can be just as effectively performed on adults. In 
addition, it is stated that children’s participation is necessary in research on children’s 
diseases and conditions to which children are particularly vulnerable. 
These attitudes are also expressed in “Guidelines for the ethical conduct of medical 
research involving children”, published by the British Paediatric Association in 1992. Many 
Norwegian pediatric researchers follow these guidelines. One of the principles found herein 
actually encourages research with children with the wording: “Research involving children is 
important for the benefit of all children and should be supported, encouraged and conducted 
in an ethical manner” (Søvik 1993). In the case of nontherapeutic research, i.e., research that 
does not necessarily benefit the patient directly, but has a general value, the CIOMS 
guidelines are more cautious than the British ones, but clearly open for this type of research: 
“Children should in no circumstances be the subjects of research holding no potential benefit 
for them unless with the objective of elucidating physiological or pathological conditions 
peculiar to infancy and childhood”. Earlier British guidelines have warned against 
nontherapeutic research with minors, while the latest now actually support this activity. 
Nevertheless, they include an explanation as to what this type of research encompasses: “We 
therefore support the premise that research that is of no potential benefit to the child subject is 
not necessarily unethical or illegal. Such research includes observing and measuring normal 
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development, assessing diagnostic methods, the use of ‘healthy volunteers’ and of placebos in 
controlled trials” (British Paediatric Association 1992). 
2.4 THE NECESSITY FOR RESEARCH INVOLVING CHILDREN 
Unfortunately, the results from medical research performed on adults cannot be directly 
transferred to children. Therefore, research on children is a necessity for a better diagnosis, 
therapy, prophylaxis and prognosis (Søvik 1975). 
Infancy is commonly considered to be an age with a great need for research. In this age 
group special illnesses and conditions arise which have no relation to adult physiology. 
Concrete examples are a condition such as jaundice, as well as lung illnesses and congenital 
heart defects. 
Other needs include establishing normal findings for the various age groups of children, 
and trying out new medicines. In addition, there is the need for knowledge about typical 
children’s illnesses which seldom, if ever, occur in adults (Søvik 1975). 
2.5 LACK OF RESEARCH – ETHICALLY JUSTIFIABLE? 
Both hospital personnel and the child patients’ parents may, of course, be skeptical to research 
involving children. This expression of care may, however, be in contrast to the importance of 
the up-to-date medical knowledge which is necessary to render the best treatment or to make 
the most correct diagnosis. The British guidelines from 1993 value the educational aspect: 
“An enquiring mind disciplined to test hypothesis by the approved canons of research while 
sensitive to the vulnerability of child patients should be seen as a valued professional asset in 
a paediatrician” (British Paediatric Association 1992). 
 Another important point to consider is the consequences of a lack of research. There is the 
risk of both a complete stop in the development of methods of treatment, and that general 
medical advice will be followed without being tested or controlled. 
An example of changes that have been made in the treatment of jaundice in newborns 
without previous systematic testing, are the criteria for the limit to the degree of jaundice 
(concentration of bilirubin, see under “What is jaundice?”) considered acceptable before 
treatment is initiated. These limits have been changed several places in the world on the 
recommendation of certain American pediatricians (Newman and Maisels 1992). 
Accordingly, the newborn is allowed a higher bilirubin concentration before phototherapy or 
exchange of blood is initiated. It is quite certain that this change in boundary criteria has not 
been systematically tested out and controlled, and that the group for which the criteria has 
been changed is large (5-10% of all newborns). After the change in these criteria was 
introduced several cases of kernicterus – the deadly result of an excessive bilirubin 
concentration – have been recorded in the USA (Hansen 1996).
There are other medical advice not necessarily based on randomized, controlled studies. 
For example, parents were earlier advised to place newborns on their stomachs to reduce the 
risk of crib death. They were later advised to lay the child on its back (Markestad 1992). The 
latter advice is based on literature and epidemiological studies. It is difficult, or course, to 
randomize newborns to one position or another both for practical and ethical reasons, the 
latter because researchers on crib death consider that they have convincing reasons to 
recommend the back-position (Rognum 1997).  However, all changes in criteria and advice 
involving children’s health require research both before and after the introduction of a change. 
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2.6 THE RISK CONCEPT IN CLINICAL RESEARCH 
A central factor in the ethical assessment of a research project is the estimated risk for the test 
person. The Declaration of Helsinki is rather general in this area, but emphasizes that medical 
research involving human subjects should only be conducted if the importance of the 
objective outweighs the inherent risks and burdens to the subject (Declaration of Helsinki, 
Part 1, paragraph 4). Again there is a need for more detail. An argument that the harm factor 
must be more extensive in research with children is presented in Ethical guidelines for 
medical research on children (Etiske retningslinjer ved biomedisinsk forskning på barn)
published by the Norwegian Research Council (NAVF) in 1983 (Utvalget for forskningsetikk 
1983). It is pointed out that a child’s personal integrity is more vulnerable than an adult’s, and 
that taking part in a research project may affect them permanently, even without physical or 
mental injury. 
Therapeutic and nontherapeutic research are handled separately in the risk assessment in 
NAVF’s guidelines. On the basis of the Declaration of Helsinki, the Norwegian guidelines 
conclude that risk per se is not acceptable in nontherapeutic research with children. When a 
protocol both includes treatment and research aspects, the risk must be substantiated in 
relationship to the benefits of the treatment. Furthermore, it is stated that the risk analysis 
shall be absolute, and made without consideration of the anticipated benefit of the research. 
An increased risk is not acceptable even when the expected benefit is large. Thus, the 
question is what comprises the risk concept. The British Paediatric Association has rated risk 
in three categories: Minimal, low and high risk. Examples of minimal risk are questioning, 
observations and blood tests taken in connection with another routine examination. The 
higher risk categories are only of interest in therapeutic research, and then only with children 
with serious illnesses. In nontherapeutic research it is considered unethical to expose children 
to more than the minimal risk. 
2.7 INFORMED CONSENT 
During the Nuremberg processes after the Second World War, German Nazi doctors defended 
themselves by contending that by exposing a relatively small number of people to 
experimentation, future generations could be spared. This argumentation was rejected on the 
grounds of the requirement for informed consent already integrated in the Nuremberg code. 
The first point in the code demands voluntary informed consent from a test subject prior to 
participation in a project. This principle is prominent in the Declaration of Helsinki as well. 
It is quite obvious that this principle cannot be applied to children, certainly not small 
children. Even if the children are mature enough to understand the contents and reason for the 
research, they are not necessarily capable to evaluate possible risks involved. According to 
the Declaration of Helsinki, informed consent must be obtained from a legal guardian when 
the test subject is a minor, and from the nearest responsible relative when the child in question 
is underage. Furthermore, it is stated that “Whenever the minor child is in fact able to give 
consent, the minor’s consent must be obtained in addition to the consent of the minor’s legal 
guardian”. Thus, it is the child, when it is mature and intelligent enough to understand the 
situation, who primarily makes the decision. In this case, the parents’ acceptance alone is 
insufficient. 
This principle is also emphasized in the guidelines from the British Paediatric Society 
from 1992 and in NAVF’s guidelines from 1983, both based on the Declaration of Helsinki 
from 1975. In the Norwegian guidelines, reference is made to paragraph 31 in the children’s 
law: “When a child has reached 12 years of age, the child shall be given the opportunity to 
express its own opinion before any decision is made regarding its personal affairs”. 
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Furthermore, the child’s opinion shall always be heard and seriously considered when the 
child is able to express its own opinion. This fact may also apply to children under 12 years of 
age. These issues in the Norwegian guidelines concur with CIOM’s guidelines. The chapter 
regarding consent states that “To the extent that is feasible, which will vary with age, the 
willing cooperation of the child should be sought, after it has been frankly informed of any 
possible discomfort and inconvenience. Older children may be assumed to be capable of 
giving informed consent, preferably also with the consent of the parent or other legal 
guardian” (point 8). It should, however, be noted that the Declaration of Helsinki provides an 
opening for not procuring informed consent in certain cases (Part II, point 5). This viewpoint 
is also expressed in the European Convention for Bioethics, article 6 (Council of Europe 
1994): “Additional informed consent from parents is unnecessary if the research is to the 
child’s advantage”. It is difficult to find evidence of this viewpoint in the interpretation of 
Norwegian law. According to Kjønstad’s (1983) article Requirements regarding consent from 
the test subject/patient in medical research (Krav om samtykke fra forsøksperson/pasient i 
medisinsk forskning), it appears to be disputable that parents have the competence to consent 
to research on their children. In the article it is claimed that this option should be more 
acceptable in therapeutic research than in nontherapeutic research, to which only limited 
acceptance is suggested. The ethical committee that approves the nontherapeutic research 
project will set strict requirements for the project (Mjølhus 1994). 
Very concrete and detailed guidelines for informed consent have recently been published 
from the American Academy of Pediatrics (Committee on Bioethics 1995). The guidelines are 
most relevant for information and consent in the treatment situation.  Also these guidelines 
indicate a trend in the direction of increased influence from the child. Concrete proposals are 
outlined as to when an older child should be allowed to make the treatment decision on his 
own.
2.8 ETHICAL PROBLEMS WITH INFORMED CONSENT 
In spite of all the work and good intentions invested in these various guidelines, certain 
difficult ethical aspects remain with regard to informed consent. 
One of these problems is that the person who provides information often has a personal 
interest in the project and may, therefore, with difficulty evaluate the risk objectively. This 
problem can be solved by recruiting a person, with no authority for clinical decision, who will 
inform the test subject or parents. Another problem is similarly associated with the 
researcher’s or doctor’s interpretation of risk. It may even be impossible to provide concrete 
information on the risk of treatment because the person involved, perhaps due to lack of 
expertise in the field, is not aware of all possible consequences of a certain treatment. A third 
difficulty is connected with the test subject’s assessment of risk. In a child’s case, one may be 
able to judge that the child is mature enough to give informed consent, but unable to 
determine how much the child understands about the possible risk, nor whether the child 
approves due to outside influence. 
Furthermore, information about an experiment may not be easy to grasp by adult test 
subjects or guardians. Lack of comprehension may be due to experience and/or education or 
for emotional reasons. Ingelfinger (1972) states the following about interpretation of 
information: “Comprehension of medical information given to untutored subjects is inversely 
correlated with the elaborateness of the material presented”. 
For example, the parents of a sick newborn child have many feelings to handle and may 
have problems understanding the implications of a possibly advanced method of treatment. 
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Or, as written in an editorial in “The Lancet” (1995): “Informed consent from poorly educated 
parents entering a complex trial in stressful conditions is a sham.” 
It is possible that many parents will give their consent for fear of coming in conflict with the 
attending physician. In certain cases a decision must be made quickly, and there is no time to 
assess the information critically enough. Levene and coworkers (1996) report that more 
parents agreed to participation in a study of sick newborns when they were asked two hours 
after the birth (76 %) than one to two weeks after birth (43 %). This fact could be due to a 
lack of time for consideration, but also to the fact that many mothers are not necessarily as 
strongly bound to their children the first days after birth and, thus, assess the elements of risk 
in the investigation less carefully (Christensen et al. 1992b). 
Requesting informed consent from a family in a difficult situation can seem so unpleasant 
for some clinicians that they prefer to abandon the project. 
2.9 IMPROVEMENT OF PHOTOTHERAPY OF NEWBORNS 
When one shall initiate a clinical investigation which involves children, it is necessary to 
assess both the conventions and aspects discussed above, and the general plan for the 
investigation. An evaluation must be made as to whether the current demands in the area have 
been fulfilled or whether adjustments must be made in the planned investigations. Perhaps the 
investigations should be abandoned entirely. Although approval from a committee of ethics is 
required, the researchers themselves must make responsible assessments, especially since 
sufficiently clear regulations in the area are not always found.
The following is a concrete description of the phototherapy project and the measures for 
improvement which are to be tried out. Finally, a conclusion will be drawn on the ethical 
justification for the clinical trials. 
2.9.1 What is jaundice? 
Jaundice is the term used for a yellowish tint to the skin which is caused by an accumulation 
of the pigment bilirubin in the skin and other organs. Bilirubin is a breakdown product of 
hemoglobin and similar substances in the blood. All individuals normally produce several 
milligrams of bilirubin daily due to a constant replacement of red blood cells. This 
replacement is initiated immediately after birth. In older individuals bilirubin is cleared 
through an enzymatic conversion in the liver and further transport into the bile. At birth, the 
enzyme system in the liver is not necessarily sufficiently developed enough to handle the 
conversion of large amounts of bilirubin. More than half of all newborns show signs of high 
bilirubin levels, and five to ten per cent are treated by phototherapy for jaundice 
(hyperbilirubinemia) (Christensen and Reitan 1987). The treatment is performed to stop the 
child from acquiring excessive concentrations of bilirubin in the blood and tissues, a situation 
which can lead to brain damage and at worst death. In most instances the jaundice disappears 
by itself within a week after birth. Therefore, it may be difficult for the doctor to decide 
whether the jaundice is serious enough to require treatment or whether it is safe to let nature 
take its course and reduce the bilirubin level via ripening of the enzymatic processes. 
2.9.2 Phototherapy 
The mode of operation and practice of phototherapy have been described earlier (e.g. Jährig et 
al. 1993). The effect of light on children with jaundice was discovered accidentally by a nurse 
in England in 1956 (Cremer et al. 1958). It was observed that children that lay near a window 
recovered more quickly, and that children with jaundice benefited from a trip to the park in 
daylight. These observations led to a series of studies that explained to a large extent how the 
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treatment works. At the present time one is not sure about all details in the effect mechanisms, 
and it is hoped that further research will uncover details that can be used to improve the 
treatment. Knowledge of the effect mechanism is particularly pertinent with regard to what 
light dose is required to convert sufficient amounts of bilirubin and prevent a concentration 
that may cause brain damage (Tan 1982). Similar to excessive doses of other medicines or 
unnecessarily high exposure to radiation in connection with x-ray diagnostics, an overdose of 
phototherapy is not recommended or of advantage. 
The color of the light can also have a great influence on the reactions that take place in 
the bilirubin, and several researchers recommend the use of long wavelengths (green instead 
of blue light).  The reason for this recommendation is that the effect can be greater in the 
green area, and also that blue light has a greater effect on other biomolecules (closer to 
ultraviolet radiation). Blue light can, therefore, involve a greater risk for undesirable reactions 
in the exposed tissue than green light. 
The treatment normally begins one to two days after birth. The child lies naked with its 
eyes protected under white or blue light provided by overhead therapy lamps. Alternatively, a 
fiber optic “blanket” can be wrapped around the child’s stomach and back, or the child can lie 
on a transparent mattress with light underneath. The intensity of the light (irradiance, 
measured in mW/cm²) and the distance from the subject vary (Christensen et al. 1992a). The 
duration of the treatment is one or more days. Blood tests of the child are taken regularly to 
determine if the concentration of bilirubin indicates a termination or continuation of the 
phototherapy. If the bilirubin concentration has increased, it may be necessary to employ 
exchange transfusion (replacement of blood). It is common practice in Norwegian hospitals to 
remove the child from the phototherapy unit for nursing and care at nonsystematic periods of 
time. 
2.9.3 Planned clinical studies 
In our study of phototherapy we will explore three parameters of treatment in relation to their 
ability to reduce the bilirubin concentration in the blood of newborns. Only overhead 
phototherapy lamps will be used in this project. Firstly, we will determine if a continuous or
fractionated treatment is optimal. (In this case, continuous treatment is defined as three hours 
under light for every hour away from the lamp, and fractionated treatment is defined as every 
other hour under and away from the lamp.) Secondly, we will investigate how effectively the 
bilirubin concentration is reduced with relation to the irradiance of the light meaning that the 
child will lie at different distances from the lamp. Thirdly, we will study the influence of the 
wavelength of the light on the breakdown of bilirubin. Blue light tubes or a blue-green lamp 
will be used as phototherapy devices. The blue-green lamp has been newly developed for this 
purpose and has previously been used in limited clinical studies (Donzelli et al. 1995). In 
addition, we will look into three biochemical parameters with regard to possible side effects 
of the treatment, namely the light-sensitive vitamins A and B2 (riboflavin) and the hormone 
melatonin (which varies according to daily rhythm, Kennaway et al. 1996). About 300, 
otherwise healthy newborns with jaundice comprise the basis for different treatment groups 
randomized to four hospitals in Norway. A summary of the various treatment groups is 
presented in Figure 1. 
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Color Intensity Regimen 1 h 1 h 1 h 1 h 1 h 1 h etc. 
BLUE HIGH CONTINUOUS 
BLUE MIDDLE CONTINUOUS
BLUE LOW CONTINUOUS
BLUE HIGH FRACTIONATED
BL-GR HIGH CONTINUOUS 
BL-GR HIGH FRACTIONATED
Fig. 1 The distribution of light and dark periods in the planned clinical investigation (BLUE: Blue light tubes, 
BL-GR: Blue-green lamp). In the dark time periods the light is turned off, the eye protection removed, and the 
parents are free to be with the child for care and nursing. Radiation continues according to the same schedule 
until the bilirubin value has fallen to a predetermined standard level. For control, blood tests of the child are 
taken every seventh or eighth hour, performed in the same way as in routine treatment. 
2.9.4 Practical consequences of the difference between conventional and research 
treatment
Only blue light tubes and the blue-green lamp shall be used in the project, not white light, 
fiber optics or the transparent mattress that are otherwise widely used in maternity wards at 
hospitals. Psychologically, these blue and green wavelengths can appear to be more unnatural 
and less comfortable to look at than white light. The present study omits the above-mentioned 
alternative devices, the use of which considerably facilitates nursing, care and bodily contact 
with the infant. The so-called “mother-child friendly alternative” includes the infant being in 
the mother’s room day and night, always accessible for nursing, if the mother so wishes. The 
aim is to provide good conditions for nursing and to increase the bond between mother and 
child. For practical reasons this alternative cannot always be performed for infants who need 
medical treatment, an argument which also applies to infants with the need for phototherapy. 
For the children in this particular study, the periods of time the child lies under or outside the 
overhead therapy lamps will be controlled. The child cannot be removed from the lamps 
without consideration. The necessity of this scheme must be evaluated individually - for 
example, if the child cries and obviously needs a rest. The children participating in the project 
will, however, receive a total of more and systematically light-free periods than what is usual 
with the use of overhead therapy lamps. As mentioned earlier, the child must wear eye 
protection while under the lamps, despite possible discomfort and inconvenience. 
As noted previously, the irradiance on the child is dependent upon the child’s distance 
from the lamp, and how many and which type of light tube is used. This equipment has 
already been adapted for use in the test treatments. The irradiance is adjusted by varying the 
numbers of lamps turned on and by modifying the dispersion of light by hanging a sheet or 
paper in the light area. The “low” irradiance described in the tests is no lower than that which 
is in general use at many hospitals (Christensen et al. 1992a). The test treatment requires the 
same number of blood tests as conventional treatment. Somewhat more blood will be taken 
than in routine tests, but in the same manner. The blood tests will be taken at predetermined 
intervals. 
2.9.5 Ethical aspects of the test treatment 
This project is supported by the Norwegian Research Council and is approved by the ethical 
committee in Health Region IV. All the various treatments to be tested have been or are in 
use, although not systematically and not necessarily in Norway. Even the irradiance termed as 
“low” in our study, is within the values routinely used in Norwegian hospitals. Therefore, it 
cannot be claimed that the treatment offered in our study is inadequate compared to standard 
treatment. We add no new forms of treatment, but utilize some that have seldom been 
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practiced in spite of researchers’ recommendations – for example, systematic fractionated 
treatment or the use of blue-green light (Jährig et al. 1995). Blood tests are taken of these 
children, regardless of whether they are receiving conventional or test treatment, and the small 
extra amount of blood drawn causes the child no discomfort. On the other hand, it may be 
ethically questionable that the blood samples are presently stored for an unknown period of 
time. Information about the test subject will be received and kept on file according to standard 
regulations at a health care institute (Norwegian Radiation Protection Authority, Radiation 
Medicine Dept.). 
As with other test treatments, general ethical questions arise with the use of children, 
especially newborns, in research. The parents of the test subject must give their informed 
consent to allow the child to participate in the study. As mentioned earlier, it is especially 
difficult to request informed consent from parents in a possibly stressful situation shortly after 
a birth. This problem may be left unsolved because it is impossible to delay the decision when 
the child needs immediate treatment. The question to the parents will not be whether or not 
the newborn shall receive treatment, but which type of light equipment shall be used. 
Equipment with very different technical design is found in Norwegian hospitals 
(Christensen et al. 1992a). We assume that the doctor, midwife or nurse chooses the 
equipment to be used in conventional treatment without consulting the parents. This aspect is, 
therefore, not particularly different when comparing conventional treatment and test 
treatment. 
In all events, the treatment will be terminated when the bilirubin level is reduced to 
justifiable levels. Possible complications or the need for supplementary treatment will be 
handled in the same way, regardless of whether or not the child participates in the test project. 
The test treatment is so similar to the conventional one that the risk involved is minimal 
compared with the already very limited risk associated with the customary implementation of 
phototherapy and accompanying collection of samples, etc. 
By consequential analysis, it can be concluded that carrying out the research project may 
be of great benefit for three main reasons: Based on research knowledge of phototherapy the 
investigation will not lead to less effective treatment of the newborns than will the 
conventional treatment. The results from the experiment may lead to improved treatment of a 
large group of newborns (approx. 2500 children in Norway annually), since the treatment 
time can be shortened so that contact with parents and environment becomes more natural. 
Furthermore, there is the possibility that the use of blue-green light may be more gentle with 
respect to biological damage than pure blue light, and that the possibilities for side effects are 
less, accordingly. 
2.10 CONCLUSION 
The described project “Optimizing phototherapy of newborns with hyperbilirubinemia” has a 
valid justification for research: There are great variations between recommended and 
practiced treatment, there is a large group of children that are affected by phototherapy, and 
the research cannot be carried out as effectively on adult test subjects or test animals. The 
study can be characterized as therapeutic research. It is beneficial for the individual receiving 
a treatment which, if different from the conventional treatment, is probably superior. Similar 
to conventional treatment, the risk involved in the test treatment is minimal. 
On the other hand, as discussed in the chapter “Ethical problems with informed consent”, 
there are a number of problems connected with informed consent when the research involves 
children, especially newborns. These aspects must be taken into careful consideration, and it 
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is, therefore, important that both written and verbal information are presented to the parents in 
the best possible manner. 
The project raises few or no serious ethical problems, and the regional committee of 
ethics that reviewed the test protocol had no objections. Thus, the project conforms to the 
restrictions of Norwegian legislation and the applicable guidelines. 
Generally, it is a problem for the ethical considerations that Norway lacks concrete, 
updated guidelines in conformity with the country’s legislation. NAVF published its Ethical
guidelines for biomedical research on children (Etiske retningslinjer ved biomedisinsk 
forskning på barn) fifteen years ago. There the problem is described in the following way: 
“According to Norwegian legislation, it appears clear that one cannot on another’s behalf give 
consent to operations which involve a real risk for physical or psychic damage, nor does the 
legislation instruct a citizen to run such a risk on another’s behalf under conditions that are 
relevant for the research situation”. 
However, it seems clear that research, also on children, can be justified by its necessity. 
The performance of the research should make great demands on the researcher’s and the 
ethical committee’s responsibility. 
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ABSTRACT
There is a need for clinical investigations of various parameters influencing 
phototherapy. The study of adverse effects related to the irradiation is based on 
inspection experience and few international guidelines. The protocol for a planned 
and partly accomplished multi-centre study is presented. Blood samples from 
jaundiced newborns subjected to phototherapy of various durations were analysed for 
the light sensitive vitamins riboflavin (vitamin B2), flavoenzymes and retinol (vitamin 
A). The serum riboflavin concentration showed a significant decrease to half its pre-
treatment value after seven hours of phototherapy, whereas the flavoenzymes 
concentration remained constant. The retinol concentration even increased during 
phototherapy. 
4.1 INTRODUCTION  
Despite the frequent use of phototherapy as treatment of hyperbilirubinemia there 
have been relatively few controlled clinical studies aimed at optimising the therapy 
with respect to irradiance, fractionation regimens, wavelength and the simultaneous 
assessment of adverse effects (Bruzell Roll and Christensen, 1997 (Paper 1)). The 
need for optimisation is based on the knowledge that phototherapy is, unlike most 
administration of medication, not a standard procedure, neither internationally nor 
nationally. Investigations of the national practices of phototherapy in 1986 
(Christensen and Reitan 1987), 1989 and 1991 (Christensen et al. 1992), and 
internationally in 1996 (Hansen 1996), in addition to our experience after inspection 
of several hospitals nation-wide throughout the period 1996-2002, revealed the 
existence of a variety of equipment for the treatment of hyperbilirubinemia. The 
lamps inspected emitted a wide range of wavelengths including UVA, and irradiances 
varied between 0.2 and 3.3 mW/cm2 in the blue wavelength region (Christensen and 
Reitan 1987). In general, there was no systematically planned fractionation or control 
of the dark-and light periods. 
In Norway, optical radiation in medicine is regulated through the Act on Radiation 
Protection and Use of Radiation (Act No. 36 of 12 May 2000. In Norwegian). Section 
13 expresses that the use of radiation in medicine must be justified and optimised. 
However, the law offers no dose limits. In fact, the only organ dose limits for blue 
light in phototherapy apply to the eyes (Matthes 1999), resulting in the requirement of 
eye protection of the treated infants. For shorter wavelengths, on the other hand, there 
are dose limits prepared by the International Electrotechnical Commission in an 
International Standard (IEC 2000) drawn up for infant phototherapy equipment. 
Taking the widespread use of phototherapy (5-10 % of all newborns) into account 
systematic studies on the effect on clinical and haematological parameters are few 
(Jährig et al. 1993). Among the studies listed are the bilirubin/albumin binding, 
oxygen binding capacity of erythrocytes, spherocyte formation, osmotic fragility, 
amino acid metabolism, fatty acids concentration and serum enzymes activity. A 
decline in the riboflavin (vitamin B2) concentration in serum of patients receiving 
phototherapy has been observed (Gromisch et al. 1977). However, a deficit is made 
up within days (Jährig et al. 1993). A phototherapy effect on another light-absorbing
vitamin, retinol (vitamin A) has, to our knowledge, not been studied.
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On this background, we planned and partly carried out a multi-centre trial including 
jaundiced newborns to be subjected to a phototherapy protocol for investigation of 
variation in irradiance, fractionation regimen and wavelength. The aim was to monitor 
the formation of photoisomers of bilirubin and the simultaneous reduction in ZZ-
bilirubin in addition to the total serum bilirubin (TSB) concentration during 
phototherapy as a measure of the efficacy of the various treatments. The serum 
samples taken to determine TSB and photoisomers were also analysed to determine 
the variations in riboflavin and vitamin A concentrations before, during and after 
phototherapy for the various treatments. For several reasons we did not succeed in 
accomplishing the entire study. Three hospitals participated in the study in a way that 
produced material for analysis, however, the number of patients was less than a tenth 
of the planned inclusion number. The irradiation regimens of the participating 
hospitals were not comparable. Nevertheless, we were able to obtain serum samples 
from 25 patients, and results from riboflavin and vitamin A analyses are presented. 
4.2 PROTOCOL FOR CLINICAL TRIALS 
4.2.1 Prepared protocol for multi-centre clinical trials 
Clinical trials were prepared in four Norwegian hospitals. The number of children to 
be included in the trial was approximately 250-300. The treatment regimens, as well 
as the order, were randomised between hospitals. 
4.2.1.1 Treatment regimens (Table 4.1) 
I.  Comparison of wavelengths 
a) Blue light (Four Philips 20W/52 tubes. Emission peak: 450 nm. Tubes must be 
covered with plexiglass) 
b) «Turquoise light» (Four Osram tubes. Emission peak: 490 nm. Tubes must be 
covered 
     with plexiglass). The turquoise fluorescent tubes were a gift from Dr. Giovanni 
Agati, 
     CNR, Firenze, Italy. Not commercially available (Ebbesen et al. 2003). (See 
4.2.1.2. Phototherapy units, irradiance and calibration) 
II. Comparison of continuous and intermittent treatment 
a) Continuous: 3 h light on, 1 h light off 
b) Intermittent: 1 h light on, 1 h light off 
III. Comparison of irradiance 
a)   High:       2 mW/cm2
b)   Normal:  1 mW/cm2
c)   Low:       0.5 mW/cm2
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Therapeutic light colour Irradiance level Irradiation regimen
Blue 
1. Low 
2. Medium 
3. High 
Continuous
Blue High 
1. Continuous 
2. Intermittent 
1. Turquoise 
              2. Blue 
High Continuous 
Table 4.1. Clinical trial irradiation regimen plan. 
4.2.1.2 Phototherapy units, irradiance and calibration 
Equipment: Air-Shields PT 533-2E (Fluoro-liteR) equipped with four light tubes 
(Philips 20W/52 or the non-commercial turquoise Osram tubes) with draping (white, 
thin cotton-sheets) or the overhead phototherapy equipment available at the hospital. 
Irradiance was measured using a UDT (United Detector Technology 371, Hawthorn, 
CA) radiometer. To determine the irradiance of the fluorescent tubes the probe 247 
(similar sensitivity at 490 and 450 nm) was used. The readings were adjusted for the 
cosine angular response by measurements of the irradiance of the blue light tubes with 
probe 268Blue (peak sensitivity of 450 nm). The tubes were placed at a distance from 
the bed (or incubator) giving irradiances of 1.3 ± 0.03 mW/cm2 as measured by the 
probe 247 and corrected to 2 ± 0.04 mW/cm2 (“high irradiance”) by the probe 
268Blue.
The photodiode was recently calibrated prior to the onset of the studies by the supplier 
and again in our optical lab in advance of the study period. The irradiance of the 
phototherapy units was checked regularly by the instrument. 
4.2.1.3 Blood samples  
a) Total serum bilirubin concentration analysed by the diazo reaction method 
performed routinely in the hospital labs. 
b) Relative concentration of photoisomers of bilirubin in serum determined by high 
pressure liquid chromatography analysis. 
c) Riboflavin (vitamin B) and retinol (vitamin A) analysed commercially. 
In addition to the blood samples the tissue bilirubin concentration will be measured 
with non-invasive reflectance spectroscopy technology.
4.2.2 Practical protocol check-list 
4.2.2.1 Inclusion criteria
Where hyperbilirubinemia is suspected, a blood sample is taken. The serum bilirubin 
concentration indicates treatment. In one hospital the bilirubin concentration criteria 
for phototherapy are as follows: Full-term (t37 weeks) at day 3: 350 PMPremature 
( 37 weeks) at day 3: 180 PM. For the three other hospitals the criteria are (day 3): 
1.5 kg: 175 PM, 1.5-2.5 kg: 225 PM, ! 2.5 kg: 275 PM.
Assess whether the infant is eligible to be included in the phototherapy project 
according to the following inclusion criteria: 
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x not too premature (t1500 g, t32 weeks of gestation) 
x no other substantial illnesses
-negative Coombs’ test 
-no RDS (respiratory distress syndrome), sepsis, serious hypoglycaemia, serious 
birth-
 defects 
-no babies in their first day of life 
x babies on parenteral diet due to lack of nursing can be part of the study if otherwise
    healthy
Babies needing more than one treatment can enter the trial again, but as «new» 
patients. 
Babies not included in the project at their first treatment may be included at a later 
treatment. However, parents are not asked a second time to include their baby in the 
project after first having refused. 
4.2.2.2 Information to parents: informed consent 
Norwegian guidelines for paediatric clinical trials follow the Helsinki declaration and 
the guidelines from the British Paediatric Association. The project is approved by a 
national ethical committee. A pamphlet was prepared called «Information to parents 
of children participating in the phototherapy project» as a supplement to personal 
communication between parents and health personnel. 
4.2.2.3 Phototherapy initiation procedures 
Blood samples are obtained by heel stick. 
A zero-point blood sample must be drawn as close to the treatment onset as possible. 
This zero-point blood sample is taken in addition to those taken on routine basis for 
checking the bilirubin level. Subsequently, samples are taken 7, 15 and 23 hours after 
treatment onset, and then every eight hours. 
A timer is connected to the phototherapy unit, and is set to the 3+1 h or the 1+1 h 
regimen. 
Make sure the hospital staff (nurses/midwives/doctors) is aware of the following: 
x the baby is supposed to stay under the light when the light is on 
x the baby must be turned around (back/front) after every «dark»-period 
x routine observations to be written in the baby’s protocol is also to be written on the 
phototherapy form placed on the bed 
4.2.2.4 Phototherapy termination  
Duration of the phototherapy is normally between one and three days. 
The treatment is terminated according to the hospital cessation criteria.
4.3 MATERIALS AND METHODS 
Serum samples were obtained from three different irradiation regimens: 16 patients 
received “Blue light, normal irradiance, continuous treatment”, four patients received 
“Blue light, high irradiance, intermittent treatment” and five patients received 
“Turquoise or blue light, high irradiance, continuous treatment”. Samples were 
collected according to the study protocol during the years 1998-2001 and kept frozen 
at -80°C until time of analysis (2001). The samples were analysed for riboflavin 
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(vitamin B2) and all-trans retinol (vitamin A) concentrations by a commercial 
laboratory (Vitas AS, Forskningsparken, Oslo. www.vitas.no). In addition to the 
riboflavin concentration the concentrations of the flavocoenzymes flavin adenine 
dinucleotide (FAD) and flavin mononucleotide (FMN) were measured. 
4.3.2 Vitamin analysis procedure
Retinol (vitamin A, all-trans retinol): 
Human plasma was diluted with 2-propanol containing the internal standard TMMP-retinol and BHT 
as an antioxidant. After thorough mixing (15 min) and centrifugation (10 min, 4000 g at 10 °C), 
supernatant was injected into the HPLC system. HPLC was performed with a HP 1100 liquid 
chromatograph (Agilent Technologies, Palo Alta, CA, USA) with a HP1100 single wavelength UV 
detector operated at 325 nm. (Column temperature: 40 °C). Retinol was separated from the matrix and 
internal standard on a 4.6 mm x 25 mm reversed phase column. A two-point calibration curve was 
made from analysis of plasma calibrators with known retinol concentrations. Recovery is > 95 %, the 
method is linear from 0.1-10 µM at least and the limit of detection is 0.01 µM. RSD is 4.9 % (1.2 µM) 
5.8 % (1.7 µM)). 
Riboflavin (vitamin B2) and flavocoenzymes: 
Human plasma was added to 20 % trichloroacetic acid . The acid conditions hydrolysed FAD to FMN. 
After thorough mixing (15 min) and centrifugation (10 min, 4000 g at 10 °C), the sample was 
incubated at 70°C for 30 minutes. Supernatant was then injected into the HPLC system described 
above, except in this analysis the HPLC was equipped with a HP1100 fluorescence detector (emission: 
520 nm, excitation: 450 nm). B2 vitamers were separated on a 2.1 mm x 50 mm reversed phase column 
with a methanol –water gradient. A four-point calibration curve was made from analysis of a 3 % 
albumin solution enriched with known concentrations of the B2 vitamers. Recovery is > 95 %, the 
method is linear from 2-42 µg/L at least and the limit of detection is 0.3 µg/L. 
4.3.3 Statistics  
Wilcoxon Signed Ranks test were used as appropriate (software package: SPSS 11.0).  
4.4 RESULTS AND DISCUSSION 
The vitamin concentrations were grouped according to exposure-time of phototherapy
irrespective of treatment regimen due to the low number of samples from two of the 
groups. Samples taken up to and including 31 h of light treatment were included. The 
sample material consisted of less than six samples in each time-group after 31 h, and 
hence, these samples were not included. In a few instances, when the sample 
collection times followed the hospital routine rather than the protocol, the samples 
were grouped with the times of best correspondence (approximately ± 3 h).  
After 7 h of phototherapy the riboflavin concentration decreased to half the mean 
zero-time concentration (Fig. 4.1) and stayed at this lower concentration level 
throughout the treatment period. The reference values for riboflavin in plasma of 
infants (6-37 months) have been reported in the literature to be 12.7 - 53.4 nM (4.8 - 
20 µg/l) (Capo-chichi et al. 2000). These numbers are lower than the mean riboflavin 
concentrations of the newborns in our study prior to phototherapy (22.7µg/l, SDEV ± 
29). This finding indicates that evaporation of (some of) the samples may have 
occurred. 
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Fig. 4.1 Mean serum riboflavin concentration of jaundiced newborns before and during phototherapy 
(Philips 20W/52 or non-commercial turquoise Osram lamp). Irradiance: 1-2 mW/cm2. ±SEM n0h=23, 
n7h= 20, n15h= 15, n23h=9, n31h=5.*: Different from [riboflavin] before phototherapy, p<0.05. 
Riboflavin has one of four absorption maxima at 447 nm (in aqueous solution). This 
absorption minimum enables the molecule to undergo photoreduction caused by 
wavelengths from blue phototherapy light. Flavins are known to catalyse several 
substances by phototsensitisation. In these processes, triplet flavin transfers energy to 
oxygen to yield singlet O2 (Sisson 1987). For this reason, riboflavin is not 
recommended as a photosensitiser to increase the effect of phototherapy (Jährig et al. 
1993).
A reduction in the riboflavin concentration in infant serum during phototherapy has 
been described by Sisson et al. (1976) and Gromisch et al.(1977) among others. There 
have been speculated that the riboflavin shortage would cause a greater haemolysis, 
disturbing the phototherapy effect and possibly lead to anaemia (Jährig et al. 1993). 
However, Jährig (1980) found no greater frequency of anaemia during long-term 
follow up. The riboflavin deficit was determined by Tan et al. (1978) to be prevented 
by 0.3 mg riboflavin daily, indicating no need for general riboflavin substitutions. 
However, more recently it has been suggested to increase the daily recommended 
riboflavin dose from 60 µg/100 kcal to 200-300 µg/100 kcal in preterm infants 
receiving prolonged phototherapy (Hansen 1993). 
The sample size of the group comparing blue and turquoise wavelengths was too 
small to detect any possible differences between the two irradiation colours. It may be 
speculated that the turquoise light with emission peak of 490 nm could have a lesser 
photodegrading effect on riboflavin than blue light with an emission peak (450 nm) 
being almost identical to the absorbance peak of riboflavin (447 nm). Elucidation of 
any correlation between wavelength and riboflavin concentration clearly requires a 
wavelength comparison study. 
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Coenzyme derivatives of riboflavin are FAD and FMN. Together with riboflavin 
these are among the biologically most important flavins. The sum of FAD and FMN is 
expressed as flavocoenzyme concentration in Fig. 4.2. Although the flavocoenzymes 
are highly sensitive to light their concentrations stay constant throughout 31 h of 
phototherapy, perhaps due to a lesser distribution in the body tissues and fluids 
compared to riboflavin. Reference values of FAD and FMN in infant plasma as 
determined by Capo-chichi et al. (2000) are 53.5 – 108.2 nM and 9 - 25.1 nM, 
respectively. For comparison, based on the mean value of the molecular weights of 
the two enzymes, the mean concentration of the sum of FAD and FMN prior to 
phototherapy in our study is 11.6 nM. Taking evaporation of the samples into 
consideration as discussed in the case of riboflavin, the real concentration may be 
even lower, pointing to increased instability of the enzymes during storage, thawing 
and freezing. 
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Fig. 4.2 Mean serum flavoenzyme concentration (sum of flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN)) of jaundiced newborns before and during phototherapy (Philips 20W/52 or 
non-commercial turquoise Osram lamp). Irradiance: 1-2 mW/cm2. ±SEM n0h=25, n7h= 20, n15h= 15, 
n23h=9, n31h=6. 
The retinol concentration shows a significant increase after 15 h of phototherapy, with 
a further increase after 31 h (Fig. 4.3), thus being unaffected by irradiation of the 
applied wavelengths in our material. The mean concentration obtained prior to 
phototherapy was 0.5 µM, which is lower than the reference level for infants (0.62-1.7 
µM) 0-1 months old (Aruplab 2003) and lower than the concentration of 0.7 µM 
considered to indicate vitamin A deficiency (Moran and Greene 1998). The low 
retinol values may be caused by the long storage.  
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Fig. 4.3. Mean (all-trans) retinol concentration of 25 jaundiced newborns before and during 
phototherapy (Philips 20W/52 or non-commercial turquoise Osram lamp). Irradiance: 1-2 mW/cm2.
±SEM n0h=25, n7h= 19, n15h= 15, n23h=9, n31h=6.*: Different from [retinol] before phototherapy, p<0.01. 
Although unsupplemented preterm infants have shown low retinol levels (Moran and 
Greene 1998), it is evident that the preterm neonates of the intensive care units in our 
study receive more vitamin A than do their term “peers” in the maternity ward (Fig. 
4.4). The latter group does most likely receive adequate levels despite the low 
concentrations shown in the figure, as breast-fed infants of well-nourished mothers do 
not show signs of vitamin A deficiency (Olson 1987). Any supplementation of 
vitamin A may have caused a masking of a possible photodegradation of the vitamin. 
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Fig. 4.4 Mean (all-trans) retinol serum concentration of jaundiced newborns irrespective of 
phototherapy in three hospitals (D, U and L) and two types of units; intensive care (white rods) or well-
baby (grey rods). Bars: ±SEM. *: Sign. different from maternity wards L and D, p<0.05 **: Sign. 
different from intensive care D and maternity wards L and D, p< 0.005. From left to right: n (patients) 
= 10, 5, 4 and 4 and n (serum samples) = 51, 15, 11 and 12. 
In summary, the serum samples collected from four hospital wards show a decrease in 
the riboflavin (vitamin B2) concentration to half the initial concentration after seven h 
of phototherapy (various regimens) followed by a  relatively constant concentration 
level throughout the 31 h irradiation period. On the other hand, retinol (vitamin A) in 
serum samples appears to be unaffected by phototherapy.
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